Pacing and the energy envelope
What studies of pacing and the energy envelope found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 4 of 5 findings are C.
5 outcomes rated · see each below
ME/CFS: C Mixed results
Based on the strongest evidence, randomised trials and studies with no comparison group and the randomised trial (very low certainty): 11 of 18 findings are C.
10 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, pacing and the energy envelope might help some people, but research can’t show it yet. For ME/CFS, studies of pacing and the energy envelope disagree, so it’s not clear whether it helps. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Pacing and the energy envelope · Long COVID is herePacing and the energy envelope · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Post-exertional malaise2 studies · 62 people took part in pacing and the energy envelope Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); only people who finished were analysed.
Studies with no comparison group2 studies · 62 people with results
Post-exertional malaise improved.
The evidence is very uncertain about the effect of pacing and the energy envelope on post-exertional malaise in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Only people who finished were analysed
See the 2 studies
-
- People in the study
- 31 started · 31 with outcome data
- Dose
- weekly
- Outcome
- severity of episodes
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 34 in the study · 31 with outcome data
- Dose
- RPE 0−10, weekly telephone calls with a clinician
- Outcome
- total number of PESE episodes Leeds PESE questionnaire
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 18 people took part in pacing and the energy envelope Worse F
Why this grade: Worse, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (18 in all).
Studies with no comparison group19 in the study · 18 with outcome data · 3 months · optional morning selection of 1 of 3 predefined activity pacing levels
Fatigue was worse with pacing and the energy envelope.
The evidence is very uncertain about the effect of pacing and the energy envelope on fatigue in long COVID. Worse · very low certainty F
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (18 in all)
See the 1 study
-
- People in the study
- 19 in the study · 18 with outcome data
- Dose
- optional morning selection of 1 of 3 predefined activity pacing levels
- Outcome
- Same-day fatigue on pacing versus nonpacing days
- Effect
- worse
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Overall symptoms2 studies · 117 people took part in pacing and the energy envelope Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.
Studies with no comparison group2 studies · 117 people with results
Overall symptoms improved.
The evidence is very uncertain about the effect of pacing and the energy envelope on overall symptoms in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 2 studies
-
The relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome. (2023)
- People in the study
- 86 in the study
- Dose
- —
- Outcome
- Recovery
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 34 in the study · 31 with outcome data
- Dose
- RPE 0−10, weekly telephone calls with a clinician
- Outcome
- EQ‐5D VAS overall health EuroQol EQ‐5D‐5L visual analog scale (VAS)
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily functioning2 studies · 62 people took part in pacing and the energy envelope Mixed results C
Why this grade: Mixed results, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance; the studies disagree.
Studies with no comparison group2 studies · 62 people with results
Studies disagree about daily functioning.
Studies disagree about whether pacing and the energy envelope helps daily functioning. Mixed results · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
- The studies disagree
See the 2 studies
-
- People in the study
- 31 started · 31 with outcome data
- Dose
- weekly
- Outcome
- Borg activity phase
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 34 in the study · 31 with outcome data
- Dose
- RPE 0−10, weekly telephone calls with a clinician
- Outcome
- targeted physical activity levels
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Quality of life2 studies · 62 people took part in pacing and the energy envelope Mixed results C
Why this grade: Mixed results, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); the studies disagree.
Studies with no comparison group2 studies · 62 people with results
Studies disagree about quality of life.
Studies disagree about whether pacing and the energy envelope helps quality of life. Mixed results · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- The studies disagree
See the 2 studies
-
- People in the study
- 31 started · 31 with outcome data
- Dose
- weekly
- Outcome
- EQ-5D-5L utility EuroQol EQ-5D-5L
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 34 in the study · 31 with outcome data
- Dose
- RPE 0−10, weekly telephone calls with a clinician
- Outcome
- EQ‐5D index
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
ME/CFS
Symptoms
Post-exertional malaise1 study · 488 people took part in pacing and the energy envelope Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.
Studies with no comparison group515 in the study · 488 with outcome data · three weeks
Post-exertional malaise improved.
The evidence is very uncertain about the effect of pacing and the energy envelope on post-exertional malaise in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 515 in the study · 488 with outcome data
- Dose
- —
- Outcome
- Helped them understand PEM triggers better
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)3 studies · 47 people took part in pacing and the energy envelope Mixed results C
Why this grade: Mixed results, very low certainty, from randomised trials: some concerns about bias (RoB 2); few people (74 in all); only people who finished were analysed; the studies disagree; randomised trials found mixed results.
Randomised trials2 studies · 74 people with results
Studies disagree about cognition (brain fog).
Studies disagree about whether pacing and the energy envelope helps cognition (brain fog). Mixed results · very low certainty C
- Some concerns about bias (RoB 2)
- Few people (74 in all)
- Only people who finished were analysed
- The studies disagree
Studies with no comparison group7 in the study · 3 consecutive weeks · three individual treatment sessions, one individual treatment session a week for a total of three treatment sessions (few people)
No clear change in cognition (brain fog).
The evidence is very uncertain about the effect of pacing and the energy envelope on cognition (brain fog) in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (7 in all)
See the 3 studies
-
- People in the study
- 48 randomised
- Dose
- one 30-minute 1-on-1 interactive information session, one session
- Outcome
- Neurophysiology of Pain Test (patient version)
- Effect
- worse
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Low
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
Activity Pacing Self-Management in Chronic Fatigue Syndrome: A Randomized Controlled Trial. (2015)
- People in the study
- 33 randomised · 26 analysed
- Dose
- Three individual therapy sessions of 60–90 min/wk for 3 consecutive wk
- Outcome
- Memory disturbances Chronic Fatigue Syndrome Symptom List
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 7 in the study
- Dose
- three individual treatment sessions, one individual treatment session a week for a total of three treatment sessions
- Outcome
- CIS Concentration Difficulties Checklist Individual Strength
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety2 studies · 23 people took part in pacing and the energy envelope Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (26 in all); effect size 0.45 (small).
The randomised trial33 randomised · 26 analysed · 3 consecutive wk · Three individual therapy sessions of 60–90 min/wk for 3 consecutive wk
Low mood or anxiety improved more than in the comparison group.
The evidence is very uncertain about the effect of pacing and the energy envelope on low mood or anxiety in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (26 in all)
- Effect size 0.45 (small)
How big was the difference?
0.45, small. The effect size compares pacing and the energy envelope with relaxation therapy group.
Studies with no comparison group7 in the study · 3 consecutive weeks · three individual treatment sessions, one individual treatment session a week for a total of three treatment sessions (few people)
Low mood or anxiety improved.
The evidence is very uncertain about the effect of pacing and the energy envelope on low mood or anxiety in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (7 in all)
See the 2 studies
-
Activity Pacing Self-Management in Chronic Fatigue Syndrome: A Randomized Controlled Trial. (2015)
- People in the study
- 33 randomised · 26 analysed
- Dose
- Three individual therapy sessions of 60–90 min/wk for 3 consecutive wk
- Outcome
- Mood swings
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 7 in the study
- Dose
- three individual treatment sessions, one individual treatment session a week for a total of three treatment sessions
- Outcome
- CFS Symptom List mood swings
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Sleep2 studies · 504 people took part in pacing and the energy envelope Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 26 people found no clear difference; a small benefit can't be ruled out; only people who finished were analysed; effect size 0.00 (very small).
The randomised trial33 randomised · 26 analysed · 3 consecutive wk · Three individual therapy sessions of 60–90 min/wk for 3 consecutive wk
No clear difference in sleep.
The evidence is very uncertain about the effect of pacing and the energy envelope on sleep in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 26 people found no clear difference; a small benefit can't be ruled out
- Only people who finished were analysed
- Effect size 0.00 (very small)
How big was the difference?
0, very small. The effect size compares pacing and the energy envelope with relaxation therapy group.
Studies with no comparison group515 in the study · 488 with outcome data · three weeks
Sleep improved.
The evidence is very uncertain about the effect of pacing and the energy envelope on sleep in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 2 studies
-
Activity Pacing Self-Management in Chronic Fatigue Syndrome: A Randomized Controlled Trial. (2015)
- People in the study
- 33 randomised · 26 analysed
- Dose
- Three individual therapy sessions of 60–90 min/wk for 3 consecutive wk
- Outcome
- Sleep disturbances Chronic Fatigue Syndrome Symptom List
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 515 in the study · 488 with outcome data
- Dose
- —
- Outcome
- Improved sleep
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue5 studies · 334 people took part in pacing and the energy envelope Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; no confidence interval shows an important benefit is ruled out; the studies disagree.
Randomised trials3 studies · 981 people with results
No clear difference in fatigue.
The evidence is very uncertain about the effect of pacing and the energy envelope on fatigue in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- No confidence interval shows an important benefit is ruled out
- The studies disagree
Studies with no comparison group2 studies · 20 people with results
Studies disagree about fatigue.
Studies disagree about whether pacing and the energy envelope helps fatigue. Mixed results · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (20 in all)
- Not all results were tested against chance
- The studies disagree
See the 5 studies
-
Same trial, also reported in: Adaptive pacing, cognitive behaviour therapy, graded exercise, and specialist medical care for chronic fatigue syndrome: a cost-effectiveness analysis. (2012) (clinically significant reduction in fatigue)
Same trial, also reported in: Rehabilitative treatments for chronic fatigue syndrome: long-term follow-up from the PACE trial. (2015) (fatigue (CFQ))
- People in the study
- 641 randomised
- Dose
- —
- Outcome
- fatigue (Chalder fatigue questionnaire score) Chalder fatigue questionnaire
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- High
-
Online treatment of myalgic encephalomyelitis / chronic fatigue syndrome in adolescents: a parallel groups randomised controlled trial comparing specialist cognitive behaviour therapy to activity management (2025)
- People in the study
- 314 randomised
- Dose
- up to six video calls (one assessment and up to five follow-up sessions), over approximately six months
- Outcome
- CIS fatigue severity subscale at six months Checklist Individual Strength
- Effect
- worse
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
-
Activity Pacing Self-Management in Chronic Fatigue Syndrome: A Randomized Controlled Trial. (2015)
- People in the study
- 33 randomised · 26 analysed
- Dose
- Three individual therapy sessions of 60–90 min/wk for 3 consecutive wk
- Outcome
- Fatigue Chronic Fatigue Syndrome Symptom List
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 7 in the study
- Dose
- three individual treatment sessions, one individual treatment session a week for a total of three treatment sessions
- Outcome
- CIS Fatigue Checklist Individual Strength
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 13 in the study
- Dose
- eight sessions, a single group session per week for eight consecutive weeks, 16h00, average duration of 60 min
- Outcome
- Likert-based CFQ score Chalder's Fatigue Questionnaire (CFQ)
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain3 studies · 161 people took part in pacing and the energy envelope Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 340 people in all; a small benefit can't be ruled out; only people who finished were analysed; effect size 0.00 (very small).
Randomised trials2 studies · 340 people with results
No clear difference in pain.
The evidence is very uncertain about the effect of pacing and the energy envelope on pain in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- 340 people in all; a small benefit can't be ruled out
- Only people who finished were analysed
- Effect size 0.00 (very small)
How big was the difference?
0, very small. The effect size compares pacing and the energy envelope with relaxation therapy group.
Studies with no comparison group7 in the study · 3 consecutive weeks · three individual treatment sessions, one individual treatment session a week for a total of three treatment sessions (few people)
Pain improved.
The evidence is very uncertain about the effect of pacing and the energy envelope on pain in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (7 in all)
See the 3 studies
-
Activity Pacing Self-Management in Chronic Fatigue Syndrome: A Randomized Controlled Trial. (2015)
- People in the study
- 33 randomised · 26 analysed
- Dose
- Three individual therapy sessions of 60–90 min/wk for 3 consecutive wk
- Outcome
- Muscle pain Chronic Fatigue Syndrome Symptom List
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 314 randomised
- Dose
- —
- Outcome
- pain
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
-
- People in the study
- 7 in the study
- Dose
- three individual treatment sessions, one individual treatment session a week for a total of three treatment sessions
- Outcome
- VAS Pain visual analog scale
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Breathlessness1 study · 16 people took part in pacing and the energy envelope Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 26 people found no clear difference; a small benefit can't be ruled out; effect size 0.06 (very small).
The randomised trial33 randomised · 26 analysed · 3 consecutive wk · Three individual therapy sessions of 60–90 min/wk for 3 consecutive wk
No clear difference in breathlessness.
The evidence is very uncertain about the effect of pacing and the energy envelope on breathlessness in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 26 people found no clear difference; a small benefit can't be ruled out
- Effect size 0.06 (very small)
How big was the difference?
0.06, very small. The effect size compares pacing and the energy envelope with relaxation therapy group.
See the 1 study
-
Activity Pacing Self-Management in Chronic Fatigue Syndrome: A Randomized Controlled Trial. (2015)
- People in the study
- 33 randomised · 26 analysed
- Dose
- Three individual therapy sessions of 60–90 min/wk for 3 consecutive wk
- Outcome
- Dyspnea on exertion Chronic Fatigue Syndrome Symptom List
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Daily life and health overall
Daily functioning5 studies · 806 people took part in pacing and the energy envelope Mixed results C
Why this grade: Mixed results, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; the studies disagree; randomised trials found mixed results.
Randomised trials2 studies · 955 people with results
Studies disagree about daily functioning.
Studies disagree about whether pacing and the energy envelope helps daily functioning. Mixed results · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- The studies disagree
Studies with no comparison group3 studies · 508 people with results
Daily functioning improved.
The evidence is very uncertain about the effect of pacing and the energy envelope on daily functioning in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
- The studies disagree
See the 5 studies
-
Same trial, also reported in: Online treatment of myalgic encephalomyelitis / chronic fatigue syndrome in adolescents: a parallel groups randomised controlled trial comparing specialist cognitive behaviour therapy to activity management (2025) (SF-36 Physical Function subscale (SF-36-PFS) at six months)
- People in the study
- 314 randomised
- Dose
- —
- Outcome
- mean difference in physical function at 6 months 36-item Short Form Health Survey Physical Function subscale
- Effect
- worse
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- High
- Selection of the reported result
- Low
-
Same trial, also reported in: Adaptive pacing, cognitive behaviour therapy, graded exercise, and specialist medical care for chronic fatigue syndrome: a cost-effectiveness analysis. (2012) (clinically significant reduction in disability)
Same trial, also reported in: Rehabilitative treatments for chronic fatigue syndrome: long-term follow-up from the PACE trial. (2015) (impairment in daily activities (WSAS))
- People in the study
- 641 randomised
- Dose
- —
- Outcome
- physical function (short form-36 subscale score) short form-36 physical function subscale
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- High
-
- People in the study
- 7 in the study
- Dose
- three individual treatment sessions, one individual treatment session a week for a total of three treatment sessions
- Outcome
- SF-36 Physical Functioning Medical Outcomes Study 36-Item Short Form Health Survey
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 515 in the study · 488 with outcome data
- Dose
- —
- Outcome
- Functional changes after using pacing with a heart rate monitor
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 13 in the study
- Dose
- eight sessions, a single group session per week for eight consecutive weeks, 16h00, average duration of 60 min
- Outcome
- SF36-PF score SF36-v2 questionnaire (SF36-Physical Functioning domain, SF36-PF)
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Quality of life4 studies · 306 people took part in pacing and the energy envelope Mixed results C
Why this grade: Mixed results, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; the studies disagree; randomised trials found mixed results.
Randomised trials2 studies · 884 people with results
Studies disagree about quality of life.
Studies disagree about whether pacing and the energy envelope helps quality of life. Mixed results · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- The studies disagree
Studies with no comparison group2 studies · 20 people with results
No clear change in quality of life.
The evidence is very uncertain about the effect of pacing and the energy envelope on quality of life in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (20 in all)
See the 4 studies
-
Online treatment of myalgic encephalomyelitis / chronic fatigue syndrome in adolescents: a parallel groups randomised controlled trial comparing specialist cognitive behaviour therapy to activity management (2025)
Same trial, also reported in: Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT. (2024) (quality-adjusted life-years)
- People in the study
- 314 randomised
- Dose
- up to six video calls (one assessment and up to five follow-up sessions), over approximately six months
- Outcome
- QALYs Quality-adjusted life years
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
-
- People in the study
- 641 randomised · 570 analysed
- Dose
- up to 15 individual therapy sessions
- Outcome
- Incremental effect quality-adjusted life years (QALYs)
- Effect
- better (not tested)
- Risk of bias
RoB 2: High
- Randomisation process
- High
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
-
- People in the study
- 7 in the study
- Dose
- three individual treatment sessions, one individual treatment session a week for a total of three treatment sessions
- Outcome
- SF-36 quality of life Medical Outcomes Study 36-Item Short Form Health Survey
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 13 in the study
- Dose
- eight sessions, a single group session per week for eight consecutive weeks, 16h00, average duration of 60 min
- Outcome
- quality-of-life (EQ-5D-5L) score remained stable
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Overall symptoms6 studies · 1,771 people took part in pacing and the energy envelope Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; no confidence interval shows an important benefit is ruled out.
Randomised trials4 studies · 1,462 people with results
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of pacing and the energy envelope on overall symptoms in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- No confidence interval shows an important benefit is ruled out
Studies with no comparison group2 studies · 495 people with results
Overall symptoms improved.
The evidence is very uncertain about the effect of pacing and the energy envelope on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 6 studies
-
Activity Pacing Self-Management in Chronic Fatigue Syndrome: A Randomized Controlled Trial. (2015)
- People in the study
- 33 randomised · 26 analysed
- Dose
- Three individual therapy sessions of 60–90 min/wk for 3 consecutive wk
- Outcome
- Chronic Fatigue Syndrome Symptom List total score
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
Online treatment of myalgic encephalomyelitis / chronic fatigue syndrome in adolescents: a parallel groups randomised controlled trial comparing specialist cognitive behaviour therapy to activity management (2025)
Same trial, also reported in: Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT. (2024) (Clinical Global Impression scale)
- People in the study
- 314 randomised
- Dose
- up to six video calls (one assessment and up to five follow-up sessions), over approximately six months
- Outcome
- Clinical Global Impression scale
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
-
- People in the study
- 641 randomised
- Dose
- up to 15 therapy sessions, over 36 weeks
- Outcome
- recovery rates
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- High
-
Rehabilitative treatments for chronic fatigue syndrome: long-term follow-up from the PACE trial. (2015)
Same trial, also reported in: Recovery from chronic fatigue syndrome after treatments given in the PACE trial. (2013) (APT v. SMC no significant difference)
- People in the study
- 641 randomised · 604 started · 481 analysed
- Dose
- maximum 14 sessions, one-to-one sessions (maximum 14 sessions) during the first six months of trial participation, with an additional booster session offered at nine months
- Outcome
- perceived health change (PCGI) participant-rated clinical global impression of change score
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
-
- People in the study
- 7 in the study
- Dose
- three individual treatment sessions, one individual treatment session a week for a total of three treatment sessions
- Outcome
- CFS Symptom List total score
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 515 in the study · 488 with outcome data
- Dose
- —
- Outcome
- Slowing or stopping deterioration
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
In the randomised trial, as the paper reports them.
had a serious one, CBT (FITNET-NHS) vs Activity Management (AM)
Stopping because of side effects2 studies
participant withdrawal from treatment because of feeling worse
Online treatment of myalgic encephalomyelitis / chronic fatigue syndrome in adolescents: a parallel groups randomised controlled trial comparing specialist cognitive behaviour therapy to activity management (2025)Two women in the experimental group did not complete the study because of practical issues (lack of time and restricted mobility
Pain physiology education improves pain beliefs in patients with chronic fatigue syndrome compared with pacing and self-management education: a double-blind randomized controlled trial. (2010)
Side effects studies reported2 kinds
| Side effect | Studies that reported it |
|---|---|
| Worse symptoms or a flare | 5 studies |
| Fatigue | 3 studies |
All papers
- Mixed methods study of views and experience of non-hospitalised individuals with long COVID of using pacing interventions.2025 · randomised trial · 35 randomised · 28 analysed
Summary
This mixed methods sub-study of the Therapies for Long COVID (TLC) feasibility trial explored views and experiences of pacing among non-hospitalised adults with Long COVID. A total of 35 people participated in this mixed methods part; 28 completed a feasibility questionnaire at Week 12 and 19 took part in qualitative interviews. Participants were in a four parallel arm open label randomised trial: pacing app (11 enrolled; 8 questionnaire completers), pacing book (10; 10), pacing video (10; 10), or usual care (4). Participants were advised to use the interventions as often as they wished; follow-up was Week 12. Among questionnaire completers, use of the allocated intervention was 100% (10/10) for the video, 90% (9/10) for the book and 62.5% (5/8) for the app. The book was used three times or more by eight of the 10 participants over two weeks or more. Video users (n = 10) used it for two weeks or more in n = 3 and watched it on average 1.8 times. The app was used daily for three months by four of the five participants who had used it. 18 participants (64.2%) believed the intervention helped them understand how to pace usual activities; 26 (92.8%) tried pacing, and of these 13 (50%) were able to pace daily activities whereas five (19.2%) were not. One participant in the app arm had formally withdrawn. Mobile app fatigue was described without a count. The authors state limitations include the small number of participants (n = 28) who completed the questionnaire and that most participants were white and female.
- Online treatment of myalgic encephalomyelitis / chronic fatigue syndrome in adolescents: a parallel groups randomised controlled trial comparing specialist cognitive behaviour therapy to activity management2025 · randomised trial · 314 randomised
Summary
This parallel groups randomised controlled trial asked whether online specialist cognitive behaviour therapy (CBT; FITNET-NHS) improves outcomes compared with online activity management (AM) in adolescents aged 11-17 years with ME/CFS. It took place in a specialist NHS ME/CFS service in the South-West of England, with referrals accepted from across the UK. 314 patients were allocated to CBT (n=155) or AM (n=159). CBT was delivered online over six months using 19 modules; AM was delivered in up to six video calls over approximately six months. The primary outcome was the SF-36 Physical Function subscale at six months; follow-up was at three, six and twelve months post-randomisation. At six months the CBT group reported greater improvement in physical function (adjusted difference in means 8.2, 95% CI 2.7 to 13.6, p=0.003); at twelve months there was no longer evidence of a difference. The CIS fatigue scale showed greater improvement with CBT at six months (difference in means -3.9, 95% CI -6.8 to -1.0), maintained at twelve months, while Chalder Fatigue scores showed similar improvements. The CBT group recovered school time more rapidly, with just over half a day per week more at six and twelve months. One or more adverse events or serious adverse events were reported for 28 (18%) CBT participants and 18 (11%) AM participants; about one quarter of participants in each group experienced a worsening condition. CBT cost more (£1,048).
- Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT.2024 · randomised trial · 314 randomised
Summary
This parallel-group randomised controlled trial enrolled 314 adolescents aged 11-17 years with ME/CFS and no local specialist treatment centre, referred to a specialist service in South West England. Participants were randomly allocated, 155 to FITNET-NHS, a web-based cognitive-behavioural therapy programme supported by individualised written asynchronous electronic consultations, or to Activity Management delivered by videocall. Both treatments were intended to last 6 months. The primary measure was the 36-item Short Form Health Survey Physical Function subscale at 6 months. At 6 months, FITNET-NHS participants had a mean physical function score of 60.5 (standard deviation 29.5, n = 127) versus 50.3 (standard deviation 26.5, n = 138) with Activity Management; mean difference 8.2 (95% confidence interval 2.7 to 13.6, p = 0.003). FITNET-NHS participants attended half a day more school per week at 6 months, maintained at 12 months. There was no strong evidence comorbid mood disorder changed relative effectiveness. Pain and Clinical Global Impression showed similar improvement; fatigue was mixed. At 12 months no clear difference in physical function remained (difference in means 4.4, 95% confidence interval -1.7 to 10.5). Worsening condition measures were met by 39 (25%) FITNET-NHS participants and 42 (26%) Activity Management participants. Costs were £1047.51 greater with FITNET-NHS. The authors report limited sustained impact and higher cost mean it is unlikely cost-effective.
- Recruiting Adolescents With Chronic Fatigue Syndrome/Myalgic Encephalomyelitis to Internet-Delivered Therapy: Internal Pilot Within a Randomized Controlled Trial.2020 · randomised trial · 89 randomised · 76 analysed
Summary
This paper reports the initial 12-month internal pilot of a UK randomized controlled trial of internet-delivered treatment for adolescents aged 11-17 years with CFS/ME who had no access to local specialist treatment. Adolescents were referred by their general practitioner to a specialist pediatric CFS/ME service in South West United Kingdom, and recruitment and treatment were remote. Of 150 potentially eligible referrals, 89 were recruited: 44 were randomized to FITNET-NHS, a web-based modular CFS/ME-specific CBT program with individualized clinical psychologist e-consultations, and 45 to activity management (AM) delivered via Skype by a CFS/ME clinician. Both treatments were designed to last approximately 6 months. The pilot's primary outcomes were recruitment, the proportion providing 6-month outcome data, and qualitative acceptability. A total of 76 out of 89 patients provided 6-month outcome data; the abstract reports 75 out of 89 for 6-month outcome data, and the results report 75 out of 89 for 12-month outcome data. Two out of 89 actively withdrew. No serious adverse events were reported by the 89 participants; nonserious health events were reported by 10, and 1 adverse event was assessed as possibly related to trial treatment, with CFS/ME symptoms worsening. Qualitative interviews found web-based treatment acceptable overall but identified advantages and disadvantages of remote methods; most participants did not feel 3 Skype AM calls were enough, and AM was increased to 6 sessions from November 2017 onward. The authors state recruitment and retention via remote methods were feasible and acceptable.
- Rethinking the treatment of chronic fatigue syndrome-a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT.2018 · randomised trial · 641 randomised
Summary
This reanalysis used the PACE trial FOIA dataset. Participants were 641 adults with mild-to-moderate CFS defined by the Oxford criteria, randomised into four groups. All were offered at least three medical consultations. Control received no further treatment; CBT, GET, and Adaptive Pacing Therapy each received up to 15 therapy sessions over 36 weeks. At 52 weeks, protocol-specified overall improvement was 20% for CBT, 21% for GET, and 10% for Control. The CBT–Control contrast had p = .015 and the GET–Control contrast p = .010; with the six planned comparisons, the Bonferroni-adjusted threshold was 0.008, and neither comparison reached it. Available-case improvement was 22% CBT, 21% GET, and 11% Control. Protocol-defined recovery was 7% CBT, 4% GET, and 3% Control; the effect was not significant (p = 0.14 intent-to-treat; p = 0.10 available case). SF36 physical-function improvement was 44% Control, 48% CBT, and 61% GET. CFQ improvement was 13% Control, 26% CBT, and 24% GET. Long-term follow-up excluding patients who received additional GET or CBT found no significant treatment-group effect on SF-36 Physical Function (F(3,291) = 0.70, ns) or Chalder Fatigue (F(3,291) = 0.17, ns). Adverse-event measures were collected; the extracted data contain no event counts.
- The planning, implementation and publication of a complex intervention trial for chronic fatigue syndrome: the PACE trial.2015 · randomised trial · 640 randomised
Summary
The PACE trial was a four-arm randomised trial in 640 patients with chronic fatigue syndrome recruited from six clinics in England and Scotland. It compared specialist medical care (SMC) alone with SMC plus adaptive pacing therapy (APT), cognitive–behavioural therapy (CBT), or graded exercise therapy (GET). Treatment duration was not reported. Co-primary outcomes were fatigue and physical disability; outcomes were assessed at baseline, mid-therapy, the end of the main treatment phase, 1-year follow-up and long-term follow-up 2.5 years after randomisation. CBT and GET led to significantly greater improvements in both fatigue and physical disability than either SMC or APT. Adjusted effect sizes ranged from 0.5 to 0.8. There were no significant differences between APT and SMC in either primary outcome. Almost all participants (98%) provided some outcome data, and 95% provided outcome data at 12 months, with no significant differences between arms in missing data. Only 8% of participants dropped out of treatment, again with no significant difference between treatment arms. Between 82 and 88% of participants who received a therapy alongside SMC said they were satisfied, whereas 50% reported being satisfied with SMC alone. There were no significant differences in any safety measures between treatment arms. The cost of one quality-adjusted life-year (QUALY) gained was £18 374 for CBT and £23 615 for GET. The authors state that having two primary outcomes complicated the analysis, although the size of the trial gave sufficient power.
- Rehabilitative treatments for chronic fatigue syndrome: long-term follow-up from the PACE trial.2015 · randomised trial · 641 randomised · 604 started · 481 analysed
Summary
This long-term follow-up of the PACE trial surveyed participants with chronic fatigue syndrome (CFS) recruited from six secondary care clinics in the United Kingdom. In the trial, 641 participants were randomly allocated to specialist medical care (SMC) alone or SMC plus adaptive pacing therapy (APT), cognitive behaviour therapy (CBT), or graded exercise therapy (GET), given in one-to-one sessions (maximum 14 sessions) during the first six months, with an additional booster session offered at nine months. Questionnaires were sent to 604 participants; 481/604 (80%) returned usable questionnaires and were included in the analysis. Median time from randomisation to follow-up was 31 months (range 24 to 53 months). Fatigue and physical functioning were measured with self-report scales, with secondary measures of impairment in daily activities and perceived health change. The improvements in fatigue and physical functioning reported by participants allocated to CBT or GET at the final trial assessment were sustained. There were no significant differences between randomised groups in mean fatigue scores at long-term follow-up. Physical functioning was better in those allocated to CBT compared with APT (6.4, 95% CI 0.4 to 12.4, p = 0.035). Participants originally allocated to APT reported further improvements in fatigue, physical functioning, and impairment in daily activities from final trial assessment to long-term follow-up. The authors state limitations including incomplete response rate, variation in follow-up duration, self-rated outcomes, and additional treatment after the trial.
- Activity Pacing Self-Management in Chronic Fatigue Syndrome: A Randomized Controlled Trial.2015 · randomised trial · 33 randomised · 26 analysed
- Pain in chronic fatigue syndrome: response to rehabilitative treatments in the PACE trial.2014 · randomised trial · 641 randomised
Summary
To compare the effects of PACE trial treatments on pain in CFS, sometimes called ME. In total, 641 patients were recruited from secondary-care specialist CFS clinics in the UK. APT (n=159), CBT (n=161) and GET (n=160) were each added to specialist medical care (SMC) and compared with SMC alone (n=160); treatment duration was not reported, and measures were assessed at week 52. Outcomes included frequency of muscle and joint pain (0–4), other CDC painful symptoms, and fibromyalgia criteria. Less frequent muscle pain was reported with CBT versus SMC (mean difference 0.38, p=0.02), GET versus SMC (0.42, p=0.01), and GET versus APT (0.37, p=0.01). Less joint pain was reported with CBT versus APT (0.35, p=0.02) and GET versus APT (0.36, p=0.02); unadjusted joint-pain comparisons with SMC were p=0.14 for CBT and p=0.12 for GET. GET versus SMC reduced fibromyalgia (12.3% difference, p=0.01), and GET versus APT reduced fibromyalgia (9.4% difference, p=0.04). One participant withdrew consent; dropouts were 5%. Harms were not reported. The authors state they could not compare CBT and GET and that pain was measured by frequency, not severity; the hospital-based sample may affect generalisability.
- Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome.2014 · randomised trial · 641 randomised · 640 analysed
Summary
This four-arm randomised trial compared specialist medical care (SMC) alone with SMC plus adaptive pacing therapy (APT), cognitive behaviour therapy (CBT), or graded exercise therapy (GET) in 641 people with chronic fatigue syndrome (CFS) recruited from six secondary care CFS clinics in England and Scotland. Participants received up to 15 sessions of therapy if allocated to a therapy arm and at least 3 sessions of SMC; follow-up was up to one year, with adverse-event interviews at 12, 24 and 52 weeks after randomisation. One participant withdrew consent, leaving 640 in the analysis. Non-serious adverse events were common: the median (quartiles) number was 4 (2, 8) per participant, with no significant difference between treatment arms (P = .47). Serious adverse events and reactions were infrequent. Physical function deteriorated in 39 (25%) participants after APT, 15 (9%) after CBT, 18 (11%) after GET, and 28 (18%) after SMC (P < .001), with no significant differences in worsening fatigue. The authors also reported no statistically significant differences between arms in those who had an SAE, SAR, or deterioration by CGI score. Limitations included differences in NSAE reporting frequency between centres, self-rated deterioration measures, and inability to model the full distribution of NSAEs.
- Recovery from chronic fatigue syndrome after treatments given in the PACE trial.2013 · randomised trial · 641 randomised · 640 started · 640 analysed
Summary
This secondary analysis of the PACE trial compared recovery after four treatments in 641 participants recruited from six secondary care CFS clinics in England and Scotland; 640 were studied. All met Oxford criteria for CFS. Participants received specialist medical care (SMC) alone or SMC plus adaptive pacing therapy (APT), cognitive behaviour therapy (CBT), or graded exercise therapy (GET), with follow-up 52 weeks after randomization. Recovery was defined operationally using fatigue, physical function, case criteria and global change measures. Trial recovery was 22% (32/143) after CBT, 22% (32/143) after GET, 8% (12/149) after APT and 7% (11/150) after SMC. Clinical recovery proportions were similar. Adjusted odds ratios for trial recovery were 3.36 (1.64–6.88) for CBT v. APT, 3.38 (1.65–6.93) for GET v. APT, 3.69 (1.77–7.69) for CBT v. SMC and 3.71 (1.78–7.74) for GET v. SMC; APT v. SMC was 1.10 (0.47–2.58), with no significant difference. The number needed to treat for trial recovery was 7 for both CBT and GET. Some data were missing for 6% of those receiving APT and SMC and 11% for those receiving CBT and GET. Side effects and withdrawals were not reported.
- Adaptive pacing, cognitive behaviour therapy, graded exercise, and specialist medical care for chronic fatigue syndrome: a cost-effectiveness analysis.2012 · randomised trial · 641 randomised · 570 analysed
- Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial.2011 · randomised trial · 641 randomised
Summary
This randomised trial enrolled 641 patients meeting Oxford criteria for chronic fatigue syndrome from six secondary-care clinics in the UK. Participants were assigned to specialist medical care (SMC) alone (160), or SMC plus adaptive pacing therapy (APT; 160), cognitive behaviour therapy (CBT; 161), or graded exercise therapy (GET; 160). Outcomes were assessed up to 52 weeks after randomisation. Primary outcomes were participant-rated fatigue (Chalder fatigue questionnaire) and physical function (short form-36 subscale). Compared with SMC alone, mean fatigue scores at 52 weeks were 3·4 points lower for CBT (p=0·0001) and 3·2 points lower for GET (p=0·0003), but did not differ for APT (0·7 points lower; p=0·38). Mean physical function scores were 7·1 points higher for CBT (p=0·0068) and 9·4 points higher for GET (p=0·0005), but did not differ for APT (3·4 points lower; p=0·18). Compared with APT, CBT and GET were associated with less fatigue (CBT p=0·0027; GET p=0·0059) and better physical function (CBT p=0·0002; GET p<0·0001). Serious adverse reactions were recorded in two (1%) of 159 in APT, three (2%) of 161 in CBT, two (1%) of 160 in GET, and two (1%) of 160 in SMC alone. There were more serious adverse events in GET than SMC (p=0·0433); treatment dropouts did not differ (p=0·50). A minority (≤9% in every group) rated themselves much worse or very much worse, which did not differ between groups.
- A feasibility study comparing two treatment approaches for chronic fatigue syndrome in adolescents.2005 · randomised trial · 13 randomised · 11 analysed
Summary
This feasibility study asked whether a larger trial could compare common treatment approaches for chronic fatigue syndrome in adolescents. At York Hospital, 13 young people aged 8.9–16.9 years with newly diagnosed CFS gave informed consent and were randomised to Pacing or the STAIRway to Health programme; both arms included support and advice on diet, sleep, and collaboration with family. Clinic appointments ran over one year, with assessments before treatment and at one year after treatment began. Outcomes included global health, child activity ratings, school attendance, fatigue, depression, and anxiety. The total sample size analysed was 11 because of two dropouts, one from each arm. Table 3 reports that all differences showed more improvement in the STAIRway arm than the pacing arm. School attendance six months post study differed (56.1, 95% CI 6.3 to 105.7, p=0.032), as did difficulty walking and climbing several flights of stairs (0.93, 95% CI 0.02 to 1.84, p=0.046) and child-rated global health (p=0.002). Other comparisons were not significant as reported, for example school attendance during treatment (p=0.057) and fatigue (p=0.44). Harms were not reported.
- Use and Perceived Helpfulness of Different Intervention Strategies in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Depression.2026 · compared with another group · 819 in the study · 3,637 started
- Myalgic encephalomyelitis/chronic fatigue syndrome patients' reports of symptom changes following cognitive behavioural therapy, graded exercise therapy and pacing treatments: Analysis of a primary survey compared with secondary surveys.2019 · compared with another group · 1,428 in the study · 954 with outcome data
- Wearable- and Mobile App-Based Activity Pacing and Fatigue Management in Post-COVID-19 Condition: Exploratory Observational Study.2026 · no comparison group · 19 in the study · 18 with outcome data
Summary
This exploratory observational study asked whether activity pacing strategies delivered through a mobile app were associated with daily fatigue and energy in adults with post–COVID-19 fatigue. 19 adults enrolled and contributed 2182 observation days; 18 were included in complete-case analyses (2181 observation days). Participants used a Fitbit Inspire 3 wearable and the FatigueSense app for a minimum intended follow-up of 3 months. Each morning they could optionally select a pacing goal—light, balanced, or active—and reported daily fatigue on a 0-3 scale and energy on a 0-100 scale; participants chose whether to set a goal on any day. Same-day and next-day outcomes were analysed with mixed-effects linear models. On pacing days, active pacing was associated with lower same-day fatigue (β=−0.34, 95% CI −0.49 to −0.19; P<.001) and higher same-day energy (β=8.8, 95% CI 4.7-12.9; P<.001) than light pacing; balanced pacing was also associated with lower fatigue (β=−0.15; P=.008) and higher energy (β=5.8; P<.001). Next-day associations were not significant. Among 12 participants trying multiple strategies, 7 (58.3%) showed meaningful responses and 5 (41.7%) minimal or no benefit. The paper did not report harms. The authors state that confounding by indication, individual heterogeneity and other limitations prevent causal interpretation.
- Experiences of pacing with a heart rate monitor for people with Myalgic Encephalomyelitis2026 · no comparison group · 488 in the study · 50 with outcome data
Summary
This qualitative study explored experiences of pacing with a heart-rate monitor (HRM) among people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). An online international survey was completed by 488 people with ME/CFS; 27 agreed to online follow-up semi-structured interviews, and open responses from over 50 survey respondents were included in the results. Participants used pacing with an HRM; duration was not reported. There was no comparison group and no randomisation. The study measured experiences through survey open answers and interviews, analysed with reflective thematic analysis. The majority of people with ME/CFS in this study felt that pacing with an HRM is a useful management tool. Themes included benefits, negatives, support and ideal design, plus barriers, body awareness/intuition, acceptance and recommendations. Pacing with an HRM allowed at least 15 people to become more intuitive about their body and limits; some progressed so they did not need to use the HRM. People with severe ME/CFS had mixed experiences, and setting a limit was particularly difficult. Using pacing with an HRM with multiple conditions to manage could be particularly difficult. Participants highlighted that devices on the market were designed for healthy people. Side effects, withdrawals and worsening counts were not reported. The authors state limitations: interviewees were all white, participants were mainly from the UK and Europe, recruitment was by self-selection and mainly represented people who found pacing with an HRM beneficial, and diagnosis could not be confirmed.
- A Short-Term Pacing Intervention in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study in Portugal.2026 · no comparison group · 13 in the study
- Experiences of pacing with a heart rate monitor for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome2026 · no comparison group · 488 in the study
Summary
This qualitative study explored experiences of pacing with a heart rate monitor (HRM) among people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). 488 people with ME/CFS completed an online international survey, and 27 agreed to online follow-up semi-structured interviews. Participants were recruited by convenience and purposive sampling; 87% of survey participants and 88% of interviewees were female; 56% of survey respondents and 70% of interviewees were UK-based. The average length of time using pacing with an HRM was 4 years (range of 1–13 years). There was no comparison group. Open survey answers and interview data were analysed using reflective thematic analysis. Themes produced from questions were Benefits, Negatives, Support and Ideal Design; themes emerging from data were Barriers, Body awareness/Intuition, Acceptance and Recommendations. The paper reports over 30 benefits and states that pacing with an HRM allowed at least 15 people to become more intuitive about their body and the limits to their activities. The authors report that no additional ‘Negatives’ were identified that have not been previously reported. The majority of people with ME/CFS in this study felt that pacing with an HRM is a useful management tool. The authors state that randomised controlled trials are needed to determine who benefits and identify guidelines to minimise the negatives and reduce the barriers.
- Patient-reported treatment outcomes in ME/CFS and long COVID.2025 · no comparison group · 5,451 in the study · 3,925 with outcome data
- ["The idea of rehabilitation will have to be completely rethought for this illness" - Qualitative results of an online survey on patients' experiences with inpatient rehabilitation for post COVID-19 condition (long COVID)].2024 · no comparison group · 1,549 in the study · 1,191 with outcome data
- A Personalised Pacing and Active Rest Rehabilitation Programme for Post-Exertional Symptom Exacerbation and Health Status in Long COVID (PACELOC): A Prospective Cohort Study.2024 · no comparison group · 31 started · 31 with outcome data
Summary
Researchers in a long COVID community rehabilitation service in Leeds, UK, evaluated an 8-week structured WHO Borg CR-10 pacing protocol with active rest in 31 adults with persistent long COVID (median symptom duration 29 months). Participants received weekly telephone calls with a clinician and were followed to 12 weeks. The study had no comparable control group; outcomes were compared within the same participants before and after the programme. Measures included the Leeds PESE questionnaire, C19-YRS and EQ-5D-5L. The paper reports that PESE episodes decreased in number each week (15% fewer each week, 95% CI 11% to 20%, p < 0.001), and that episodes were of shorter duration and milder severity. Changes in C19YRS symptom severity and functional disability (0–12 weeks) were statistically significant but not clinically significant, and the EQ5D-5L index score change was not statistically significant. Side effects and treatment-related withdrawals were not reported. The authors state limitations including a small sample size, a lack of diversity in the patient group, no comparable control group, and that clinicians were not blinded.
- “It’s a moving target”: Experiences of pacing to reduce symptom exacerbation among adults living with Long COVID – Results from an international community-engaged qualitative research study2024 · no comparison group · 40 in the study · 37 with outcome data · preprint
- An Adaptive Pacing Intervention for Adults Living With Long COVID: A Narrative Study of Patient Experiences of Using the PaceMe app.2024 · no comparison group · 25 in the study
Summary
This qualitative narrative interview study explored experiences of the PaceMe adaptive pacing app among adults with long COVID. Twenty-five participants (19 female, 6 male, median age 47) enrolled in the PaceMe trial were recruited; each took part in two narrative interviews, with follow-up between 3 and 6 months later. The app used a Fitbit Charge 5 wearable and allocated time and heart rate limits of attempting to spend no more than 30 min per day above 60% of age-predicted HRmax, with alerts at 50%, 75%, and 100% of time limits. There was no comparison group. Analysis identified four themes: PEM management, Support, Validation, and Control and Agency. Participants described identifying PEM triggers and rest needs; many described PaceMe as the first meaningful support beyond family or partner; many described validation through confirmation or evidence; and analysis reported greater autonomy and agency. All participants expressed the view that PaceMe had been helpful in some way. The authors state limited insights regarding potential adverse aspects; one participant described alerts as “a bit stressful,” and another said they sometimes “feel a bit bereft” when the app does not sync. The paper does not report withdrawals for harms.
- Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome.2023 · no comparison group · 34 in the study · 31 with outcome data
Summary
This longitudinal prospective cohort enrolled 34 participants with confirmed or suspected COVID-19 and post-COVID syndrome symptoms for more than 12 weeks in a community COVID-19 rehabilitation service; 31 were analysed after 3 were excluded because they did not complete the full 6-week follow-up. Participants followed a 6-week structured WHO Borg CR‐10 pacing protocol for physical activity guidance, with weekly telephone calls with a clinician; there was no concurrent control group, so results are within-arm changes from Week 1 to Week 6. The mean number of PESE episodes fell from 3.4 in Week 1 to 1.1 in Week 6, with a reported average weekly decrease of 16% (95% CI 9%−24%; p < 0.001). Table 3 reports percentage decreases in episodes per week for PESE related to physical exertion (29%, 95% CI 20%−37%; p < 0.001), cognitive exertion (20%, 95% CI 12%−29%; p < 0.001), and emotional exertion (27%, 95% CI 14%−39%; p < 0.001). EQ-5D VAS overall health changed from 51.4 to 60.6 points (paired difference 9.2, 95% CI 3.2−15.2; p = 0.004), and EQ-5D index from 0.49 to 0.63 (paired difference 0.14, 95% CI 0.08−0.20; p < 0.001). There was no evidence of differences in improvement rates between subgroups by sex, age, or starting phase. Severity and duration of episodes when they occurred remained similar. Participants reporting no PESE over a 7-day period increased from 6 to 13. Four participants could not comply with protocol guidance because they were unwell with an acute viral infection separate from COVID, a second COVID-19 infection, or an exacerbation of PEM. Side-effect collection was not reported separately.
- An international survey of experiences and attitudes towards pacing using a heart rate monitor for people with myalgic encephalomyelitis/chronic fatigue syndrome.2023 · no comparison group · 515 in the study · 488 with outcome data
Summary
This online survey asked people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) who had used or were using heart rate monitoring (HRM) about their experiences and attitudes. The survey had 40 questions, was open for three weeks, and was advertised on ME websites, Twitter and Facebook pages. Of 515 respondents, 27 were excluded because they did not report a diagnosis of ME/CFS, leaving 488 analysed. There was no comparison group. Respondents reported on severity of ME, severity of PEM and period of recovery from PEM before and after HRM. Severity of ME reduced after HRM pacing (z=–5.07, p < 0.001, n = 330). PEM severity was less after HRM (Mdn = 2.00) than before (Mdn = 3.00; z=–11.11, p < 0.001, n = 377), and recovery from PEM was faster after HRM (Mdn = 2.00) than before (Mdn = 3.00; z=–9.54, p < 0.001, n = 300). Functional benefits included improved ability to do activities of daily living or self-care (31%) and improved physical capability (23%). Regarding harms, 2.2% stated they felt they had been harmed by HRM and 4.1% stated they felt they may have been harmed; 5.2% found it too difficult to continue. Of 12 people who expanded, four felt reduced activity had led to deconditioning, two felt it affected their mental health, and one felt it may have made orthostatic intolerance worse. The authors state limitations include that an official diagnosis of ME could not be checked, and statistical analyses were limited by the numbers of respondents in some groups.
- The relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome.2023 · no comparison group · 86 in the study
Summary
This retrospective study assessed pacing strategies in patients with post-COVID-19 syndrome (PCS) attending the Internal Medicine Department of Angers University Hospital, France, between June 2020 and June 2022. In total, 86 patients were included and followed-up for a median time of 10 [6–13] months. All patients were advised to apply pacing strategies; there was no separate control group. The study compared patients who recovered, improved, or did not recover/improve, and compared patients by pacing adherence. At follow-up, 29/86 (33.7%) experienced recovery and returned to work, 20/86 (23.3%) showed improvement, and 37/86 (43%) did not recover or improved. Among recovered patients, 10/29 (34.5%) returned to full-time employment and 19/29 (65.5%) returned to part-time work. The EPS score was the only variable associated with recovery on multivariate analysis (OR 40.43 [95% CI 6.22–262.64], p < 0.001). Median FSS scores changed from 6.8 [6.3–7] to 3.1 [2.6–3.3] in recovered patients, from 6.8 [6.6–7] to 4.3 [4.1–4.5] in improved patients, and from 7 [6.8–7] to 6.2 [5.8–7] in those not recovered/improved. Recovery was observed in 27/45 (60.0%) patients with high pacing scores versus 1/23 (4.3%) and 1/18 (5.5%) with moderate and low scores. Improvement was observed in 15/45 (33.3%) versus 4/23 (17.4%) and 1/18 (5.5%). Moderate and low EPS scores did not significantly differ in FSS reduction or health status. Harms were not reported. The authors state the study was retrospective and used self-reported questionnaires.
- Targeting mitochondrial dysfunction in the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - a clinical audit.2013 · no comparison group · 138 in the study · 34 with outcome data
Summary
This is an audit from a UK private practice that treats ME/CFS. It covers 138 patients who took a blood test of how their white blood cells make energy (the ATP Profile). Every patient was advised a basic regime: a stone-age diet, enough good sleep, a standard package of nutritional supplements, and the right balance between work and rest. Extra steps were tailored to each person's test results, such as far-infrared saunas or selective chelation therapy. Only 34 patients had the test repeated, between 5 and 67 months later (30 months on average); the authors have no follow-up results for the other 104. Almost everything measured was a laboratory value, and the authors report that these values rose in the 30 patients who followed the regime but not in 4 who did not follow it. For how patients felt or functioned, the paper gives only individual stories and a general statement: one woman was able to resume work part time, another was back at work 4 days per week, and the authors write that for most patients the laboratory improvements were paralleled by clinical improvements, without measuring symptoms on any scale. They state that no patient reported any harm from the treatments. There was no randomised comparison, the authors could not confirm whether patients followed the advice, and the lead clinician's income comes from treating patients.
- The search for pain relief in people with chronic fatigue syndrome: a descriptive study.2011 · no comparison group · 50 in the study
Summary
This descriptive, cross-sectional study asked people with chronic fatigue syndrome (CFS) who experienced pain which complementary/alternative medicine (CAM) and physiotherapy treatments they had tried for pain and how much benefit they perceived. 50 participants were recruited through CFS support groups across Scotland; interviews took place in their homes. 10 participants were severely affected. There was no comparison group; treatment duration and follow-up were not reported. At interview, 18 of 50 were currently receiving treatment for pain, and 3 were receiving physiotherapy. 45 participants reported previously trying 19 different CAM treatments. Acupuncture was the most frequently tried (23 participants); 14 reported benefit, and among 5 severely affected participants, 4 reported relief and 1 reported increased pain. Of 18 who tried massage, 5 reported reduced pain and 13 reported increased pain during treatment or worse the following day. Of 17 who tried reflexology, 9 reported increased pain and 4 found it beneficial. All who tried acupressure, lymphatic drainage, and hyperbaric oxygen reported improvements. 27 participants tried physiotherapy and reported 16 different interventions; spinal mobilisations, TENS, and ultrasound were reported to make no difference. 12 tried graded exercise therapy, and 11 stopped because it increased pain. For cognitive behaviour therapy, 11 reported benefit, 13 did not, and 22 refused. 41 of 50 were taking pain medication; 11 reported it eased pain, and Two were unable to take it due to side effects. Warm baths (29), heat applications (25), lying down/rest (22), and drinking water (17) were reported to ease pain.
- [Patients' experience with treatment of chronic fatigue syndrome].2009 · no comparison group · 828 in the study
- Can pacing self-management alter physical behavior and symptom severity in chronic fatigue syndrome? A case series.2009 · no comparison group · 7 in the study
Summary
The authors state there is a lack of evidence supporting pacing self-management as a treatment for chronic fatigue syndrome (CFS) and examined whether physical behavior and health status would improve. Seven adult women fulfilling Centers for Disease Control and Prevention criteria for CFS, recruited from a specialized university-based chronic fatigue center, took part. They received pacing self-management in three individual treatment sessions, one session a week for 3 consecutive weeks, after a 7-day baseline assessment period, with a 7-day posttreatment assessment period. There was no comparison group; pretreatment and posttreatment data were compared within the same participants. Physical behavior was monitored in real time with an accelerometer, and health status was assessed with the CFS Symptom List, visual analog scales for fatigue, pain and concentration difficulties, the CFS-APQ, SF-36, CIS and COPM. In the intention-to-treat analysis of seven patients, the CFS Symptom List total score improved (p = 0.043; mean improvement = 7 ± 8 mm), as did VAS concentration difficulties (p = 0.043; mean improvement = 12 ± 10 mm), muscle weakness, mood swings, intolerance to bright light and both COPM subscale scores (p = 0.043), with five of seven patients improving on both COPM subscales. A statistically significant decrease in the mean time spent doing light activity (<3 METs) was observed, while no change was found in the CFS-APQ or SF-36 (p > 0.05). Two patients ended their cooperation during the program.
- Pacing and Exercise in Chronic Fatigue Syndrome2001 · no comparison group · 2,338 in the study
Summary
This paper reports a treatment audit carried out among the membership of three national support groups: The ME Association, Action for ME and the 25% Group. The largest questionnaire had 2,338 respondents. The audit collected self-reported outcomes of pharmacological, non-pharmacological and alternative approaches; no comparison group, randomisation, duration or follow-up was reported. For pacing, 1,949 respondents found it helpful, 201 reported no change, and 30 stated they were made worse. The same largest questionnaire asked about graded exercise: out of 1,214 who had tried it, 417 believed it had been helpful, 187 reported no change, and 610 respondents (around 50%) stated that graded exercise had made their condition worse. Withdrawals were not reported. The paper states that pacing takes into account fluctuations in symptom severity and accepts periods of rest and relaxation. It also reports concerns about graded exercise programmes, including inflexible programmes and relapse. The authors conclude: 'These results indicate that pacing is a highly acceptable and effective approach to activity management in CFS/ME.' Limitations of the audit are not reported.
- Eicosanoids and essential fatty acid modulation in chronic disease and the chronic fatigue syndrome.1994 · no comparison group · 29 started · 29 with outcome data
- [Pacing in a 59-year-old female patient with post-Covid syndrome - a model for self-directed rehabilitation].2024 · case report · 1 in the study
Summary
This case report concerns one 59-year-old woman with post-COVID syndrome after a corona infection. She is described as previously healthy and active, with pronounced physical and cognitive fatigue; the abstract says inpatient rehabilitation gave no relief and that a pension was necessary. The treatment described is a pacing system with documentation of symptoms and classification into severity grades; no duration is reported. There is no comparison group, no randomisation and no crossover. The text mentions the fatigue scale for motor and cognition FSMC for assessing the extent of fatigue, but no scores are reported. The only treatment result recorded is that the pacing system enabled the patient access to her physical performance and to her emotional reactions; no direction of change, follow-up, analysed number or statistics are reported. The abstract reports no side effects, no harms and no withdrawals. The authors conclude that the patient needs patience for the healing course. No limitations are stated.
- Einsatz von Akupunktur bei Long Covid Use of acupuncture in long COVID2022 · case report · 1 in the study
Summary
This single case report describes a 32-year-old woman who developed Long Covid after Covid-19 in March 2020. Three months after infection she presented with thoracic stinging, tightness, palpitations, fatigue, and exertional dyspnea. She received acupuncture at points including Lu 5, Mi 9, Mi 6, Ma 36, Gb 41, 3E, Le 3, He 7, and PaM 3, with cupping on the posterior thorax at the beginning of treatments. Sessions were scheduled regularly every 1–2 weeks. No comparison group was used. Outcomes reported: after she stopped cycling due to a massive worsening of symptoms, her complaints improved quickly; after 6 weeks she could begin light home workouts and short bicycle rides; after 10 weeks she felt well resilient and was symptom-free. No adverse effects from acupuncture or cupping are reported. The authors state the treatment approach was the first patient they saw for Long Covid and discuss typical Qi deficiency; they do not report formal limitations.
- Overlapping Post-COVID Conditions: A Case of Myalgic Encephalomyelitis and Postural Orthostatic Tachycardia Syndrome Triggered by Sequential Epstein-Barr Virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections.2026 · combination: given with other treatments · 1 in the study
Summary
This case report describes one 48-year-old woman in Belo Horizonte, Minas Gerais, Brazil, followed at the Carlos Prates Health Center as part of VITA Monitoring. She had ME/CFS diagnosed in early 2023 and POTS diagnosed later that year after SARS-CoV-2 infection in January 2022, with PCC persisting over three years. Her regimen included pyridostigmine bromide 60 mg every 12 hours, duloxetine hydrochloride 60 mg/day (later 30 mg/day), naltrexone 2 mg/day, bupropion 300 mg/day, palmitoylethanolamide 600 mg/day (later 900 mg/day and 1200 mg/day), vitamin C 1 g/day, Omega-3, pacing, hydroxyzine hydrochloride 25 mg/day, methylprednisolone 125 mg/day for three days, and vitamin B12 1 mg/day. Follow-up was baseline (V1) and evaluations after one month (1M), three months (3M), six months (6M), and twelve months (12M). There was no comparison group and no randomisation. The report states partial improvement in fatigue, orthostatic symptoms, and memory, but worsening of hair loss; worsening of symptoms after starting light walks (10 minutes/day); and treatment responses that were partial and fluctuating, with no objective biomarkers available to quantify them. Final assessment in mid-2025 indicated partial, fluctuating symptom response and persistent functional impairment. Harms reported were worsening hair loss and worsening symptoms after starting light walks; withdrawals for harms were not reported. Table 1 presents anthropometric, vital-sign, and handgrip strength measurements descriptively; the authors state changes should not be interpreted as evidence of a treatment effect.
- Wearable Devices Enable Long COVID Patients to Decrease Symptom Severity: A Case Series From Pilot User Testing.2025 · combination: given with other treatments · 11 in the study · 9 with outcome data
- Return to work with long COVID: a rapid review of support and challenges.2025 · systematic review
Summary
This rapid review examined support for return to work in people with long COVID. Searches were completed in June 2024 across major databases including MEDLINE, Embase, PsycINFO, evidence-based medicine reviews, Web of Science and Google Scholar, and twenty-five studies were included. The review covered non-workplace-based support and workplace-based support. Non-workplace support included a telerehabilitation programme using pacing strategies and occupational therapy, pacing strategies, and a home exercise plan with moderate and intense activities. Workplace support included adjusted work arrangements, flexible hours, working from home, task changes, emotional support, financial support, and vocational integration programmes. The review reported that the telerehabilitation programme reduced the number of participants on medical leave by week eight and increased the number returning to full-time work. Patients who adhered more strictly to pacing strategies had higher recovery rates, defined as ability to return to work. A three-month home exercise plan showed no change in work ability from baseline, and the authors noted no significant WAI improvement following a home exercise plan. The review also described organisational barriers such as lack of understanding of long COVID symptoms, insufficient workplace guidance, and educational gaps among managers, and facilitators such as recognition and validation of long COVID and eligibility for disability benefits. The authors state that the search was limited to English language.
- Effectiveness and safety of exercise therapy in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a meta-analysis.2025 · systematic review
Summary
This meta-analysis asked whether exercise therapy changes fatigue and harms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The authors searched PubMed, Web of Science, Embase, and Cochrane to March 2024, with an update on June 7, 2025, and analyzed 13 studies with 1,305 patients: 659 in intervention groups and 646 in control groups. Interventions included aerobic training, guided graded exercise self-help, graded exercise therapy, gradual exercise, and Qigong forms. Control conditions included control, standard medical care, adaptive pacing therapy, CBT, and heart rate variability biofeedback. Outcomes were fatigue scale-14 (FS-14), multidimensional fatigue inventory (MFI-20), and adverse effects. The meta-analysis reported lower total, physical, and mental fatigue scores on FS-14 with exercise therapy than control; on MFI-20, physical fatigue and reduced activity improved, while general fatigue, mental fatigue, and reduced motivation did not differ significantly. Subgroup analysis reported conventional exercise was more favorable for total and physical fatigue, while Qigong was more favorable for mental fatigue. For harms, Clark et al. reported non-serious adverse events in ~1/4 of participants in both the intervention group and the control group, one case of serious adverse events in both groups, and no serious adverse reactions in either group; severe deterioration difference was not evident. Another study reported non-serious adverse events frequently, serious adverse events and severe adverse reactions relatively rare, and severe deterioration uncommon. The authors note publication bias and limitations.
- Evaluating pacing therapy (PT) versus graded exercise therapy (GET) for improving fatigue, pain, and quality of life in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A systematic review.2025 · systematic review
Summary
This systematic review examined pacing therapy (PT) and graded exercise therapy (GET) or graded exercise self-help (GES) for adults with ME/CFS, with adaptive pacing therapy (APT) and specialist medical care (SMC) as comparators. It included six studies; recorded samples were 640, 197, 957, 481 and 640, and searches were limited to English, with all studies being UK-based. Outcomes were fatigue, pain, quality of life/physical function and adverse events. Drop-outs (n = 486) meant the final analysis included 77% of the initial sample. Bourke et al. reported less frequent muscle pain with GET versus APT (p = 0.01, difference = 0.17) and SMC (p = 0.01, difference = 0.38), and greater joint-pain reductions versus APT (p = 0.02, difference = 0.15) and SMC (p = 0.07, difference = 0.22). Clark et al. reported GES scored 4.2 points lower on CFQ (p < 0.0001) and 6.3 points higher on SF-36PF (p = 0.006) than SMC; 64% versus 44% improved in fatigue and 45% versus 22% in physical functioning. White et al. reported recovery on CFQ of 33% with GET, 22% with APT, 21% with SMC; SF-36PF recovery was 53%, 35%, and 41%. Sharpe et al. found APT and SMC improved fatigue and physical functioning (p < 0.0001), not GET, with no significant between-group differences. Geraghty et al. reported 32% worsening, 49% no change, 19% improvement; PT 44% versus GET 12% improvement, and GET 74% versus pacing 14% worse. Dougall et al. reported physical functioning decline in pacing 25%, SMC 18%, and GET 11% (p = 0.0007), and pooled NSAEs were 74%.
- Identifying Factors That Might Affect Outcomes of Exercise-Based Therapies in Long-COVID.2024 · systematic review
Summary
This systematic review examined exercise-based therapies for people with Long-COVID; it included 39 studies. The search was performed from 13 February 2024 to 27 February 2024 in Pubmed, PEDro, BioMed Central, EBSCOhost, ProQuest and the ZBSport. Treatments included supervised exercise training and programs combining physical training with respiratory training, pacing or physiotherapy; some combined programs lasted >5 weeks with three individualized sessions per week. The review reports no comparison group. Outcomes covered Long-COVID symptoms, quality of life, physical fitness and pulmonary parameters. In one named study (Binetti et al.), a 3-month protocol showed no significant improvements in Long-COVID symptoms or physical fitness. Adverse events were documented in 16 studies: no adverse events were identified in 12/16 studies, and 4/16 studies reported adverse events related to the intervention. One study recorded 6–9% adverse events and 2–5% serious adverse events in the intervention and usual care groups; 21 serious adverse events and 19 admissions to hospital or prolongation of admission were reported, and one serious adverse event (syncope with vomiting 24 h after training) was possibly related to the intervention. Intervention-related adverse events included unilateral knee pain, severe anxiety before the session and headache. In a pacing study, four patients were unable to comply with guidance. There were no cases of exacerbation of symptoms after exercise during weekly monitoring. The authors state that comparison was difficult because the same parameters were examined using a wide variety of measurement methods.
- ‘Pacing’ for management of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review and meta-analysis2024 · systematic review
Summary
This systematic review and meta-analysis asked whether pacing affects symptoms in people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Six electronic databases and grey-literature websites were searched up to 16/11/2023, yielding 5 included studies. Pacing was compared with specialist medical care in the PACE trial; other included designs were uncontrolled or case series. Outcomes were physical function, pain, and fatigue. For physical function (k = 4), the pooled SMD was 0.15 (95% CI = −0.39, 0.68, p = 0.5951). For pain (k = 4), the pooled SMD was −0.11 (95% CI = −0.32, 0.10, p = 0.3090); Bourke et al. [29] observed no change to pain (SMD = −0.06), and Nijs et al. [32] (n = 7) resulted in an SMD of 0.01. For fatigue (k = 4), the pooled SMD was −1.09 (95% CI = −2.38, 0.21, p = 0.0998); the PACE trial reported a positive effect of pacing compared to the control group for fatigue, with n = 159 and n = 160 in the pacing and specialist medical care [SMC] control group respectively. Side effects and withdrawals were not reported. The authors state insufficient evidence to conclude a positive effect for physical function, pain, and fatigue, although pacing may reduce fatigue.
- The effectiveness of activity pacing interventions for people with chronic fatigue syndrome: a systematic review and meta-analysis.2023 · systematic review
Summary
This systematic review and meta-analysis asked whether activity pacing interventions, alone or with other evidence-based interventions, improve fatigue, physical function, psychological distress, depression and anxiety in people with chronic fatigue syndrome (CFS). The authors searched seven databases until 13 August 2022 for randomised controlled trials that included activity pacing interventions for CFS and a validated measure of fatigue. The review was registered as PROSPERO CRD42016036087. The number of included studies, the number of participants, participant settings, the duration of interventions and the exact comparator are not reported in the provided text. The outcomes listed were fatigue, physical function, psychological distress, depression and anxiety. The provided text reports that the review found effects at reducing fatigue, psychological distress and depression and improving physical function when compared to no treatment or usual care, and that improvement was greater for interventions that encouraged graded escalation of physical activities and cognitive activities. The authors concluded that activity pacing interventions reduce fatigue and psychological distress and improve physical function in CFS, particularly when people are encouraged to gradually increase activities. The provided text does not report side effects, withdrawals, worsening, or the authors’ own stated limitations.
- What treatments work for anxiety and depression in children and adolescents with chronic fatigue syndrome? An updated systematic review.2022 · systematic review
Summary
This systematic review updated searches from 2015 to 2020 in Cochrane Library, Medline, Embase and PsycINFO for studies of children and adolescents with CFS/ME and validated measures of depression and/or anxiety. Combined with previous reviews, 16 studies and 965 participants were included; follow-up ranged from immediately post-treatment to 21 years. Treatments included CBT, the Lightning Process, valacyclovir, pacing, gammaglobulin, placebo, and inpatient or specialist care programmes. An RCT compared Lightning Process plus specialist medical care with specialist medical care alone; the review reports adjusted mean differences in depression and anxiety scores at 6 and 12 months, for example depression −1.5 (−3.5 to 0.5, 0.1) at 6 months and −1.8 (−3.4 to −0.1, 0.04) at 12 months. An observational cohort of routine specialist care measured depression and anxiety at baseline but not post-treatment. CBT-type interventions had most evidence for improving comorbid anxiety and/or depressive symptoms, but delivery and modality varied. A trial reported a deterioration in school attendance in the pacing arm. The review reports insufficient evidence to draw conclusions, and no study specifically targeted depression or anxiety. The authors state the evidence is poor and insufficient for meta-analysis.
- A mixed-methods systematic review of post-viral fatigue interventions: Are there lessons for long Covid?2021 · systematic review
Summary
This mixed-methods systematic review asked whether post-viral fatigue interventions offer lessons for long Covid. Online databases were searched in October 2020, and 40 papers were selected. The included fatigue interventions involved 25 studies in CFS/ME, nine in fibromyalgia and eight in unexplained fatigue. Treatments varied widely and were compared with controls, typically usual care or waiting lists; fatigue severity was the main outcome. Intervention duration varied and is not quantified in the recorded data. The review reported mean differences for several interventions. The largest mean difference was for the Three Principles/Innate Health programme (MD -39.0, 95% CI -51.8 to -26.2, SMD = 1.670). Group-based CBT also showed reductions (MD -27.5, 95% CI -33.7 to -21.3, SMD = 1.170; MD -23.7, 95% CI -29.2 to -18.2, SMD = 2.266). Smaller mean differences were reported for GET (MD -11.5, 95% CI -17.6 to -5.4, SMD = 0.524) and self-regulation based physical activity (MD -9.9, 95% CI -16.3 to -3.4, SMD = 0.513). TENS (MD -6.0, 95% CI -16.9 to 4.9, SMD = 0.239), Tai Ji Quan (MD -0.4, 95% CI -9.6 to 8.9, SMD = 0.023) and supportive listening (MD 1.06, 95% CI -1.4 to 3.6, SMD = -0.111) showed little or no benefit. Doxycycline mean differences were positive (MD 6.3, 95% CI 3.7 to 8.8, SMD = -0.752; MD 8.75, 95% CI 6.36 to 11.14, SMD = -1.120). No side effects, withdrawals or worsening were reported in the recorded data.
- Cost-effectiveness of Interventions for Chronic Fatigue Syndrome or Myalgic Encephalomyelitis: A Systematic Review of Economic Evaluations.2021 · systematic review
Summary
This systematic review examined the cost-effectiveness of interventions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). It included 10 economic evaluations based on randomised controlled trials; searches covered MEDLINE (1946–2020) and EMBASE (1974–2020). The included evaluations examined CBT, GET, counselling, specialist medical care, adaptive pacing, guided support groups, fatigue self-management, treatment as usual, pragmatic rehabilitation, supportive listening and the lightning process, alone or with other care. Study sizes ranged from 100 to 640 participants. Outcomes were costs and health effects such as QALYs or fatigue scores. In the largest trial, CBT had a 59.5% likelihood of being cost-effective versus GET (34.8%), specialist medical care (5.5%) and adaptive pacing (0.2%) at £30,000 per QALY. One trial reported CBT was dominated by counselling for cost per improved fatigue score. GET versus CBT had an incremental cost of £193 and incremental effect of 0.71. GET was more cost-effective than usual care plus self-help booklet above £987 for a clinically significant fatigue improvement. For the lightning process plus specialist medical care, incremental cost was £390 and incremental effect 0.095 QALYs, with £1508 incremental net monetary benefit. Side effects and withdrawals were not reported.
- Cost-effectiveness of interventions for medically unexplained symptoms: A systematic review.2018 · systematic review
Summary
This systematic review asked whether interventions for medically unexplained symptoms (MUS) or functional somatic syndromes (FSS), including fibromyalgia, irritable bowel syndrome and chronic fatigue syndrome, are cost-effective. The search covered PubMed, PsycINFO, NHS-EED and the CEA registry to 15 June 2018 and included 39 full economic evaluations in adult patients. Interventions varied: group CBT, individual CBT, graded exercise therapy, adaptive pacing therapy, multidisciplinary rehabilitation, counselling, educational and pharmacological treatments. Comparators included usual care, waiting lists, other physical or psychological treatment and other drugs. Outcomes were incremental costs, incremental effects and ICERs, using QALYs or clinical scales. Results differed by study: in CFS, CBT and GET dominated specialist medical care on average, with ICERs of €24,475 and €31,456 per QALY; APT had an ICER of €73,576 per QALY and SMC was preferred over APT for all outcomes. MRT appeared not cost-effective compared with CBT. In fatigue, graded exercise had an ICER of €1,377 per unit of clinically significant improvement on the Chalder Fatigue Scale, and counselling was dominated by usual care plus a self-help booklet. No side-effect or withdrawal counts were recorded. The authors state language restrictions and limited comparability; they describe heterogeneity across the included studies.
- Do evidence based interventions for chronic fatigue syndrome improve sleep? A systematic review and narrative synthesis.2017 · systematic review
Summary
The review was a systematic review and narrative synthesis of eight studies, with searches completed in March 2015. Included studies enrolled adults aged 18 or over meeting Oxford and/or CDC criteria for chronic fatigue syndrome (CFS) and evaluated CBT, GET, or combined approaches with a sleep outcome. Studies evaluated 12 weeks of individual graded exercise sessions (29), a 12-week group cognitive behavioural stress management programme (44), a 2-participant case study, pragmatic rehabilitation with 2 sessions (37), 2 sessions plus telephone contact (39), or 7 sessions (38) versus standardised medical care (34), 10 sessions of multi-convergent therapy (12), 10 nurse-led pragmatic rehabilitation sessions (95), and 24 weeks of individual CBT (161) or GET (160). One GET study found no significant difference in PSQI ratings; another reported significant improvements in sleep difficulties for CBT and GET compared with APT and specialist medical care. A CBSM pilot found reduced frequency, but not severity, of unrefreshing sleep. Powell et al. (2001) reported significant PR improvements at 3, 6 and 12 months; Wearden et al. (2010) reported improvement at 20 weeks but not at 70 weeks. The case study reported ratings decreased from 18 & 19/20 to 0. Thomas et al. reported a significantly greater number of participants with improved sleep in the MCT group. No harms events were recorded. The authors state that the small number of studies and differences in design, sample inclusion criteria and outcomes meant strong conclusions could not be made.
- What treatments work for anxiety in children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)? Systematic review.2017 · systematic review
Summary
This systematic review asked what treatments work for anxiety in children with CFS/ME. The authors searched Medline, Embase and psychINFO in July 2016 and included nine papers from eight studies of children under 18 years with CFS/ME and a valid anxiety assessment. None targeted anxiety as a primary outcome; six treatment studies measured anxiety as a secondary outcome. Four used CBT-type approaches, one a behavioural approach, and one compared intravenous gammaglobulin with placebo. Sample sizes ranged from 1 to 135. In Chalder et al, 23 participants (18 at follow-up) received a CBT-based rehabilitation programme; anxiety improved significantly at 6 months, and the 20 participants who completed treatment returned to school, with 19 of 20 attending full time. Lloyd et al enrolled 63 participants in telephone CBT; anxiety improved significantly (treatment effect estimate −0.49, p=0.003), school attendance improved from 24% to 49%, and fatigue reduction was not significant. Nijhof et al randomised 135 (112 at long-term follow-up) to FITNET internet-delivered CBT or usual care; full school attendance was 50 (75%) vs 10 (16%), and 63% were defined as recovered compared with 8%. Wright et al randomised 13 (11 at follow-up) to STAIRway or pacing; the anxiety difference was −1.60, p=0.6, and school attendance deteriorated in the pacing arm. Rowe et al recruited 71 (70 at follow-up) to gammaglobulin or placebo; anxiety reduced in both arms. The authors state insufficient evidence to conclude the best treatment.
- Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.2015 · systematic review
Summary
This systematic review examined treatments for adults with ME/CFS. It included 35 treatment trials in 45 publications; trials enrolled predominantly middle-aged women from ME/CFS specialty clinics and used CFS case definitions. Treatments were compared with placebo, usual care, wait-list, relaxation, adaptive pacing, CBT, or other therapies. In 2 fair-quality trials (n=324), rintatolimod improved cardiopulmonary exercise test tolerance (36.5% versus 15.2%; P=0.047), exercise duration (10.3% versus 2.1%; P=0.007), and exercise work (11.8% versus 5.8%; P=0.01). In a small trial of 30 participants, valganciclovir improved fatigue on 1 scale but showed no statistically significant differences for other measures. Trials of galantamine, hydrocortisone, IgG, isoprinosine, and fluoxetine indicated no beneficial effects but were limited by small numbers. Counseling and behavior therapies improved fatigue, function, quality of life, work impairment, and global improvement in some trials (low to moderate strength of evidence). A meta-analysis of 4 CBT trials found no statistically significant difference in SF-36 physical function (weighted mean difference, 10.42 [95% Cl, -3.86 to 24.69]); a sensitivity analysis found 6.02 [Cl, 1.05 to 10.88]. GET improved function (10.68 [Cl, 6.32 to 16.88]), fatigue (4 trials, n=619), and global improvement (relative risk, 1.58 [Cl, 1.24 to 2.47]). In the PACE trial, deterioration of physical function was 25% with adaptive pacing, 18% with usual care, and 11% with GET (P<0.001). Harms included galantamine: 90% reported harms and 2% serious events, none attributed to study drug; IgG headaches 93% versus 60%; GET serious adverse events 17 versus 7. GET withdrawals were 37% versus 22%, and 20% declined repeat exercise testing. Adverse effects were rarely reported overall.
- Interventions in pediatric chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review.2013 · systematic review
Summary
This systematic review searched CINAHL, PsycINFO and Medline to May 2012, with a limited update in October 2012, for studies of interventions in children and adolescents with CFS/ME. It included 24 articles based on 21 studies, with variable designs and quality. In Wright (2005), 13 participants were randomized to a structured tailored incremental rehabilitation program or pacing; the review reports improvements in activity and school attendance with the program immediately after treatment compared with pacing. Viner (2004) reported 43% of the treatment group had complete resolution of CFS/ME compared with 4.5% with supportive care. Lim (2002) reported that before an inpatient program 94% attended school less than half-time, and 78% attended full-time or with occasional absences only at follow-up. Szyndler (2003) reported problem improvement or resolution in 31% by clinician rating and 86% by family rating. Van Geelen (2010) reported 52% nearly complete improvement and 48% no improvement. For harms, Rowe (1997) reported adverse effects common, and Nijhof (2012) reported no serious adverse events. The authors state that methodological inadequacies and inconsistent approaches limit interpretation.
- How to exercise people with chronic fatigue syndrome: evidence-based practice guidelines.2012 · systematic review
Summary
This systematic literature review asked which exercise modalities should be used for people with chronic fatigue syndrome (CFS). It included 12 studies of adults and/or children diagnosed with CFS by official criteria, and examined graded exercise therapy (GET) and cognitive behavioural therapy (CBT) interventions. Treatments were compared with control interventions such as flexibility or relaxation therapy, with adaptive pacing therapy (APT), or with different doses of GET. Outcomes were fatigue and physical functioning. The review reports that the included studies confirm a positive effect (P <0Æ05) of CBT and GET on fatigue and physical functioning. In the PACE study, CBT and GET were associated with significantly less fatigue (CBT, P =0Æ0027; GET, P <0Æ0059) and improved physical function (CBT, P =0Æ0002; GET, P <0Æ0001) compared with APT. A comparison of three GET intervention groups found no significant difference in fatigue or physical functioning, but a similar improvement (P <0Æ001) in all three groups compared with the control group. Flexibility or relaxation therapy alone did not significantly improve (P >0Æ05) fatigue or physical functioning. The authors conclude that exercise therapy should be aerobic and comprise 10–11 sessions over 4–5 months, with home exercises five times a week starting at 5–15 min and increasing to 30 min. Side effects and withdrawals were not reported. The authors state the findings should be interpreted with some caution.
- Cognitive behavioral therapy and graded exercise for chronic fatigue syndrome: A meta‐analysis.2011 · systematic review
Summary
This meta-analysis asked whether cognitive behavioral therapy (CBT) and graded exercise therapy (GET) show positive effect sizes in chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME). Twenty studies were included: five GET trials (N = 170) and 16 CBT trials (N = 1,457); one trial contributed an effect size to both groups, leading to a total of 21 effect sizes. Trials were identified through database and reference searching in April 2011. CBT and GET were compared with control conditions and with each other. CBT treatment contact across trials ranged from 6 to 16 hours. Outcomes were post-treatment fatigue, anxiety, depression and functional impairment. The pooled overall effect size was g = 0.26 (CI = 0.08, 0.43) for GET and g = 0.33 (CI = 0.23, 0.43) for CBT. Fatigue effect sizes were g = 0.41 for GET and g = 0.36 for CBT; functional impairment g = 0.39 for GET and g = 0.36 for CBT; depression g = 0.15 for GET and g = 0.32 for CBT; anxiety g = 0.01 for GET and g = 0.15 for CBT. There were no significant differences between the two treatment types on overall outcome or the four outcome categories. Across studies, a median of 12% of GET participants (range = 10–18) and 17% of CBT participants (range = 0–46) dropped out of treatment or did not complete post-treatment assessment measures. Worsening and side effects were not reported.
- Pharmacological and non-pharmacological management of long COVID.2026 · review
Summary
This narrative review synthesized current evidence on non-pharmacological, pharmacological and probiotic management of long COVID, searching Google Scholar and PubMed for peer-reviewed articles "published up to January 2025"; the authors state that no standardized protocols exist. Reported non-pharmacological data included an online-guided 3-month exercise intervention in 62 patients with post-COVID syndrome that "demonstrated benefits in terms of physical performance," although "overall exercise capacity and quality of life did not improve significantly," and a retrospective study of 86 individuals with post-COVID-19 syndrome in which "patients with high adherence to pacing experienced significantly greater recovery and symptom improvement compared to those with low or moderate adherence." In a randomized, double-blind, placebo-controlled, multicenter trial of 200 participants, "By day 14, fatigue resolution was significantly higher in the intervention group compared to the placebo group (91% vs. 15%)," and "The supplements were well tolerated, with no adverse effects reported." In one study of 38 participants, 19 were given VSL#3 and 19 received a placebo, with "Significant improvement in physical functioning, a decrease in fatigue, and alleviation of gastrointestinal problems" in the probiotic group, while "there were no discernible improvements in the symptoms of somatization, anxiety, depression, or performance." In 36 individuals, after 12 weeks of low-dose naltrexone plus NAD+, "fatigue scores were considerably reduced"; "The iontophoresis patches were associated with only mild, short-lived skin irritation in 25% of patients."
- Pacing and energy management with digital tools for conditions with chronic fatigue: What we know so far in ME/CFS and Long COVID.2026 · review
Summary
The paper reports a 6-month randomised controlled trial of PaceMe, a pacing platform combining a wearable activity tracker with just-in-time messages based on a personalised activity allowance, in people with Long COVID. The number of participants and the recruitment setting are not reported. PaceMe was compared with usual care. The primary outcome was PEM measured with the DePaul Symptom Questionnaire-PEM (DSQ-PEM). The paper states the intervention was not superior to usual care. It reports no adverse events and says qualitative feedback indicated users felt greater insight and control. It does not report how many people worsened, stopped, or withdrew. The authors state that Long COVID may exhibit gradual improvement over several months, which could obscure differences between groups in pacing trials that focus on PEM; they also state it is equally plausible that there is a null effect of digital energy management on PEM frequency and severity. They recommend future testing in conditions without expected recovery, such as ME/CFS.
- EFFECTIVENESS OF THERAPEUTIC INTERVENTIONS FOR CHRONIC FATIGUE SYNDROME: A NARRATIVE REVIEW2026 · review
Summary
This narrative review summarized treatment studies in chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME). A structured search of PubMed and Google Scholar, with ResearchGate used only to retrieve full texts, was performed in June 2026 and covered publications from 2001 to 2025; of 132 identified publications, 54 were included. Treatments included CBT, exercise-based interventions, nutritional supplements (CoQ10, NADH, selenium, creatine, combination nutraceutical therapy), rituximab and rintatolimod. Five nutritional studies assessing 265 patients reported significant fatigue improvement (p < 0.001 to p = 0.038); three studies involving 192 patients reported significant sleep improvement (p = 0.008–0.018), while one study of 27 patients receiving CoQ10 + selenium found no effect on sleep (p = 0.480). Two CoQ10 studies involving 171 patients reported significant quality-of-life improvement (p = 0.001–0.048), whereas two studies involving 46 patients found no improvement (p > 0.05). In the RituxME phase III trial, clinical response was 26.0% (20/77) with rituximab vs 35.1% (26/74) with placebo (p = 0.22); adverse events occurred in 81.8% vs 64.9%. In exercise studies, deterioration in health status was observed in 27.6% (367/1331), and 2.1% discontinued treatment due to worsening health (3% GET vs 1% AM). No advantage of GET over comparator groups was found in three different studies. The authors state that included studies differed substantially in design, diagnostic criteria, interventions, follow-up duration and outcome measures, and findings were synthesized qualitatively.
- The role of herbal medicine in supporting cognitive dysfunction associated with long COVID: Review2026 · review
Summary
This review examined herbal medicine for cognitive dysfunction associated with Post-COVID-19 Condition (PCC). The search covered PubMed, Scopus, ProQuest, and Cochrane for English-language papers with search parameters between January 2020 and November 2025; five primary clinical studies were included. These were a case study series of 5 patients given EGb761® (Ginkgo biloba); a single case of one 55-year-old female given Hochuekkito with other treatments; a prospective pilot study of 45 participants given Bojungikgi-tang, Kyungok-go, or Cheonwangbosim-dan; a retrospective cohort of 47 patients given Traditional Chinese HMs; and an RCT of 78 participants comparing Triphala with placebo. Durations varied across studies. Outcomes included cognitive severity and cognitive tests, fatigue, respiratory symptoms, emotional distress, oxidative stress, inflammatory biomarkers, and self-report questionnaires. EGb761® appeared to substantially improve cognition in all five patients, with mean time to improvement 10.6 weeks (range 7–16 weeks). The single case reported NRS reducing from 5 to 0 and BFI from 7.0 to 0.5, and TMT-A improving by 10 s. Kim et al. reported no significant between-group cognitive change (p = 0.1225), with 14 participants lost to follow-up. Hsieh et al. reported fatigue and respiratory improvements, but emotional distress changes were not significant. Intakhiao et al. found no significant between-group change in cognitive function; fatigue and headache improved in both groups, and respiratory symptoms were lower than placebo (p = 0.025). No significant adverse events were reported in the Zifko, Kim, or Intakhiao studies. Worsening or stopping was not reported. The authors state the evidence is heterogeneous and methodologically limited.
- Assessment and management of post-COVID-19 pulmonary complications: a rapid review.2026 · review
Summary
This rapid review assessed evidence on management and treatment of pulmonary complications in post-COVID-19 condition (PCC). It included 73 unique records from published and grey literature; these comprised guidance documents, secondary studies and primary research studies. Included primary studies involved adults with PCC and pulmonary complications, with individual study sizes that included 28 and 871 participants. Interventions included IHHT plus standard rehabilitation, nirmatrelvir plus ritonavir, hyperbaric oxygen, systemic corticosteroids, and multicomponent exercise rehabilitation. Comparisons included standard rehabilitation, placebo plus ritonavir, sham treatment, nonsteroid care, and usual care or control. Outcomes included 6MWT distance, Borg and PROMIS dyspnoea, RAND-36 physical function, FEV1, FVC, FVC % pred, resting oxygen requirement and adverse events. Doehner 2024 reported a significant between-group difference in 6MWT distance favouring IHHT plus rehabilitation (p<0.001). Geng 2024 found no between-group difference in PROMIS dyspnoea (p>0.05). Kjellberg 2025 found no difference in RAND-36 physical function (p=0.277) or 6MWT distance (p=0.62) with hyperbaric oxygen versus sham. Ntiamoah 2024 reported significant improvements in FEV1, FVC and FVC % pred in the steroid group only. Torres 2024 reported FVC % pred improved from 52±0.17% to 60±0.20% (p=0.019) and resting oxygen requirement reduced (p=0.005), with no significant change in 6MWT distance (p=0.50). Seo 2025 reported diarrhoea in 80% of patients with nintedanib; Ora 2023 reported no adverse events with sodium pyruvate nasal spray. The authors state study quality and risk of bias were heterogeneous and findings should be interpreted with caution.
- Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): diagnosis and management.2025 · review
Summary
This narrative review searched PubMed, Web of Science, Embase, and the Cochrane Library from inception to August 2025 and included 211 publications on ME/CFS diagnosis, pathophysiology, assessment, and treatment. It summarized pharmacological and non-pharmacological interventions. Reported examples include a double-blind, randomized, placebo-controlled trial of IVIG in 99 CFS patients that found an absence of dose-dependent efficacy; a Phase III rintatolimod study in 208 ME/CFS patients in which 51.2% of a severely debilitated subgroup (n = 21/41) had a ≥ 25% improvement in exercise treadmill test duration; a 12-week trial in 207 ME/CFS patients reporting significant reductions in fatigue with CoQ10 (200 mg) and nicotinamide adenine dinucleotide (20 mg); LDN showing significant improvement in 73.9% of 218 ME/CFS patients; and a pilot study of 55 ME/CFS patients in which oral minocycline produced favorable symptom improvements for 80% of treatment completers. A pooled analysis of 1,298 ME/CFS patients from eight trials associated CBT with significant reductions in fatigue severity and functional impairment. A pragmatic trial in 241 adolescents (aged 8–17) found no significant inter-group difference between GET and activity management for physical function on the Short-Form 36 at 6 months. A systematic review and meta-analysis reported a significant reduction in fatigue (Hedges’ g = -0.52) and an improvement in physical function with pacing compared with no treatment or routine care. Harms included GET-associated symptom exacerbation in a significant proportion of patients, and rintatolimod adverse events may occur. TCM findings should be cautiously interpreted because the available evidence is constrained by methodological limitations.
- The PACE Trial's GET Manual for Therapists Exposes the Fixed Incremental Nature of Graded Exercise Therapy for ME/CFS.2025 · review
Summary
This review examined evidence used by White et al. about NICE guidance for ME/CFS; it did not enrol or treat participants. In the PACE trial, quality-of-life scores at 24 weeks and 52 weeks were 0.60 (GET) and 0.61 (CBT), and 0.59 (GET) and 0.63 (CBT), and CBT and GET did not have an effect on CFS symptom count. The review states 20% of PACE participants who improved subjectively deteriorated objectively (6MWT). In MAGENTA (n = 241; GET 123, AM 118), there was no evidence GET was better or more cost-saving than AM at 6 or 12 months; accelerometer activity fell at 3 and 6 months. GETSET showed no indication of an advantage or disadvantage of GET versus SMC for physical performance, and a significant difference at 15 months favouring SMC for fatigue. In Moss-Morris et al., subjective physical functioning improved 30% after GET while CPET deteriorated 15%. Reported harms included worsening in 58.3% (CBT) and 81.1% (GET) in an Oxford Brookes University study (n = 2274), and 14% (CBT) and 22.4% (GET) becoming bedridden; 82% of a 25% ME group survey (n = 437) were made worse by GET, and an Action for ME survey reported GET harmful in 60% of cases. A Dutch GET programme reported dropout of 55%, 73%, and 80% at 6, 9, and 12 months. The authors report no formal limitations section.
- Rehabilitative interventions in patients with persistent post COVID-19 symptoms-a review of recent advances and future perspectives.2024 · review
Summary
This review examines rehabilitative interventions for people with persistent post COVID-19 symptoms. It reports no patient numbers and no setting. In a randomized controlled trial in post COVID-19 patients with post-traumatic stress disorder, psychological treatment plus narrative exposure therapy was compared with psychological treatment alone; the intervention group showed larger, although non-significant, improvements in anxiety, depression, and sleep quality. A prospective study of a structured pacing protocol over 6 weeks in post COVID-19 condition with PEM/PESE reported a reduction in mean PEM/PESE episodes per week from 3.4 to 1.1, increased activity level, and significantly improved quality of life. Cognitive behavior therapy over 8 weeks in ME/CFS was reported to show significant improvements in physical and mental fatigue. Early pulmonary rehabilitation in post-COVID-19 patients compared with non-COVID-19 respiratory failure patients reported a 6 min walk distance increase of + 205 m versus + 93 m. A comprehensive 3-week inpatient pulmonary rehabilitation program reported vital capacity + 11,3% and 6 min walk distance + 124 m. An indirect comparison reported 6-min walk distance 380 m vs. 468 m for comprehensive inpatient rehabilitation versus no rehabilitative intervention. The review states that cognitive behavior therapy should be used with care to avoid distress and that upright exercise should be avoided because orthostatic intolerance occurs in this position. Side-effect, withdrawal, worsening and stopping counts are not reported; the authors state that most evidence comes from observational trials without control groups and that randomized trials of comprehensive interdisciplinary rehabilitation are missing.
- A Multidisciplinary Approach: Management and Rehabilitation of Children With Pediatric Post-COVID-19 Condition.2024 · review
Summary
This paper is an experience-based clinical guideline, not a trial, on management and rehabilitation of children with pediatric post-COVID-19 condition (PPCC). The authors report no enrolled patients, no comparison group, no randomisation, and no follow-up numbers. They describe a multidisciplinary, individualized approach focused on symptom management, energy management, and return to daily activities. The guidance includes education about PPCC, pacing to balance activity and rest, and a goal-oriented return to school and social activities. It advises stimulating light physical activity for 20 minutes a day, such as going for a walk, and starting physical aerobic or anaerobic training only if reintegration towards sports has already started and there are no more signs of PEM. The authors state that pacing has not been proven through clinical trials as a treatment strategy for PPCC. They cite a review by Sanal-Hayes et al. in adults with ME/CFS reporting that pacing was self-reported to be the most preferred form of activity management; the same cited review noted that some studies found no effects and one reported worsening of symptoms in 14% of their study population. The guideline reports no results or harms from its own study. The authors state that scientific evidence on management, rehabilitation, and treatment strategies for children is scarce, and treatment based on pathophysiology does not yet exist.
- Effects of graded exercise therapy and medical care on chronic fatigue syndrome2024 · review
Summary
This review article examined five studies published between 2013 and 2023, identified through PubMed, on treatments for CFS/ME in the working population. The interventions reviewed were GET, CBT, APT, SMC, and GES. The review reports that in White et al. (2013), with 641 participants over 52 weeks, recovery was CBT 22%, GET 22%, APT 8%, and SMC alone 7%; the chances of recovery were significantly higher for CBT and GET than for APT and SMC alone. In Sharpe et al. (2015), a follow-up of the 641 participants, 75% returned the long-term questionnaire and 44% received additional treatment; reduced fatigue and better physical and cognitive functioning were sustained for those originally assigned CBT or GET, while those initially assigned SMC or APT also improved. Clark et al. (2017) included 211 participants, with 107 assigned to GES and 104 to control; after 12 weeks, 34% of the GES group showed 8 points of improvement on SF-36 and 3 points on CFQ, compared with 14% improvement in the control group. Wilshire et al. (2018) reported that the GET group had better physical function ratings but not fatigue self-assessment, while the CBT group had better fatigue self-assessment but not physical function. Clark et al. (2021) reported that 78% returned questionnaires 15 months after commencement; GES improvements were sustained but without additional improvement and no significant difference compared to control. Side effects and withdrawals were not reported in the text. The authors state limitations concerning reliance on self-reported questionnaires and variability across studies.
- A scoping review of 'Pacing' for management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): lessons learned for the long COVID pandemic.2023 · review
Summary
This scoping review searched six electronic databases up to 02/02/2022 and included 17 studies of pacing in people with ME/CFS. Designs were heterogeneous: RCTs, observational studies, a case series, and PACE trial sub-analyses. Pacing interventions included educational sessions, activity diaries, activity pacing self-management, and the energy envelope; comparators included relaxation therapy, pain physiology education, graded exercise therapy, cognitive behavioural therapy, and specialised medical care, while observational studies had no intervention. Outcomes covered symptoms, fatigue, physical function, pain, quality of life, self-efficacy, sleep, depression and anxiety. Findings were mixed. Antcliff et al. reported pacing improved mean scores of all symptoms; Kos et al. reported improved COPM performance (33% of group), satisfaction (42% of group), and CIS; Nijs et al. reported both improvements in CFS, COPM, and VAS and no improvement in SF-36, CFS, or CIS. White et al. reported pacing did not improve fatigue or physical function, but CBT and GET did. Geraghty et al. reported improved symptoms in 44% of respondents and worsened symptoms in 14%. Dougall et al. reported pacing worsened physical function in 25% of the group versus SMC 18%, GET 11%, and CBT 9%. White et al. reported recovery in 8% with pacing versus CBT 22%, GET 22%, and SMC 7%. Drop-outs were reported (Kos 25% experimental, 18% control; Meeus 5%; Nijs 22%; White 8%).
- The Draft Report by the Institute for Quality and Efficiency in Healthcare Does Not Provide Any Evidence That Graded Exercise Therapy and Cognitive Behavioral Therapy Are Safe and Effective Treatments for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.2023 · review
Summary
This review examined the draft IQWiG report and the three trials it used on CBT and GET for ME/CFS: Janse et al. 2018, GETSET, and PACE. The PACE trial was a non-blinded study with n = 641. The review reports ME/CFS and notes long COVID/post-COVID syndrome. Setting and treatment duration were not reported. Treatments included iCBT/odCBT/pdCBT, GES, CBT and GET, compared with SMC or APT. Outcomes included adherence, CGI change, fatigue, physical functioning, six-minute walk test, step test, employment status, quality of life, symptom count and harms. Adherence was 16% (odCBT) and 19% (pdCBT); in GETSET, 43 (42%) adhered completely or very well, 31 (30%) moderately well, and 30 (29%) slightly or not at all. CGI positive change was 14% (GES) and 6% (SMC). At 52 weeks, fatigue scores were 20.3 (CBT) and 20.6 (GET); physical functioning scores were 58.2 (CBT) and 57.7 (GET). CBT and GET did not lead to objective short-, medium- or long-term improvement on the six-minute walk test; the step test showed no objective improvement. CBT had no effect and GET a negative effect on employment status. Quality-of-life net improvement was 2.3% after GET over APT and 0.5% after CBT over APT. Symptom-count improvement showed no statistically significant difference (p = 0.0916; p = 0.23; p = 0.0986). Cited surveys reported 20 percent of respondents said CBT worsened health and at least 50% for GET; an Oxford Brookes survey (n = 2274) reported worsening in 81.1% (GET) and 58.3% (CBT).
- What interventions or best practice are there to support people with Long COVID, or similar post-viral conditions or conditions characterised by fatigue, to return to normal activities: a rapid review2023 · review · preprint
Summary
This rapid review asked what interventions or best practice support people with Long COVID, or similar post-viral conditions characterised by fatigue, to return to normal activities. It included ten relevant studies published between 2014 and 2022: systematic reviews, primary studies and guidelines. The primary studies covered Long COVID and CFS. One survey of 145 UK workers recovering from COVID-19 found that only 15% managed a full return to work. A longitudinal cohort of 111 patients with CFS after mononucleosis described a written self-management programme; there was an 18% increase in patients in employment from baseline (10% in employment) to follow-up (28% in employment). A case study of 1 patient with Long COVID reported improved depression and anxiety symptoms and improved quality of life and work and social adjustment after management therapy. A qualitative study of 8 healthcare professionals reported gradual return to work as a frequently mentioned accommodation. The reviews reported that exercise therapy, electrical nerve stimulation, sleep and touch therapy, and behavioural self-management may be beneficial; in one review exercise therapy may have a positive effect on fatigue compared with usual care or passive therapies. Four of five interventions in one review found statistically significant benefit, while music therapy combined with CBT reported no significant benefit. Side effects were not counted; one review was uncertain about the risk of side effects. The authors state little reported evidence of effectiveness and weak overall evidence.
- Evidence-Based Care for People with Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.2022 · review
Summary
This narrative review describes rehabilitative treatments for CFS/ME. It does not report a new study; it summarizes trials. The main trial discussed is PACE, a four-arm trial that recruited over 600 patients. PACE compared specialist medical care alone with specialist medical care plus CBT, GET, or adaptive pacing therapy. Outcomes included functioning, fatigue, and six safety outcomes. The review states that CBT and GET improved functioning and reduced fatigue more than specialist medical care alone or specialist medical care plus adaptive pacing therapy. It reports no evidence of harm from CBT or GET in PACE. A more recent trial of guided self-help based on GET found no significant differences in safety outcomes compared with specialist medical care. The review also notes patient group surveys reporting that rehabilitation and GET in particular made some patients worse outside trials, and that rigidly applied programmes not tailored to symptom severity and disability may lead to worsening symptoms. No patients, enrollment numbers, follow-up durations, or withdrawal counts are reported for the review itself.
- The Updated NICE Guidance Exposed the Serious Flaws in CBT and Graded Exercise Therapy Trials for ME/CFS.2022 · review
Summary
This review examined the evidence that Flottorp et al. used to support CBT and GET for ME/CFS after NICE's updated guidance. The review enrolled no patients itself; it discussed trials in ME/CFS, including PACE (n = 641), Gordon et al. (n = 22), Chalder et al. (n = 63), Windthorst et al. (n = 28) and an Oxford Brookes University study (n = 2274). Reviewed treatments included CBT, GET, APT, SMC, graded aerobic exercise, resistance training, I-CBT and waiting-list or usual care. In PACE, the chronic fatigue syndrome symptom count showed no statistically significant difference between GET and SMC (p = 0.0916), GET and APT (p = 0.23) or CBT and APT (p = 0.0986); EQ-5D net improvement was 2.3% after GET over APT and 0.5% after CBT over APT. Gordon et al. found no intervention significantly better than the other for any outcome. In Gotaas et al., the physical functioning difference between I-CBT and control was 6.8 points, below the authors' 10-point minimal important difference, and dropout was 20.5% vs. 6%. Oxford Brookes reported worsening in 58.3% (CBT) and 81.1% (GET); bedridden status increased from 12.6% to 26.6% (CBT) and 12.9% to 35.3% (GET). GETSET reported 14% (GES) and 6% (SMC) positive change, with only 8% subjectively benefiting from GES and up to 59% not tolerating treatment well. No limitations of the review were stated.
- Patients' experiences and effects of non-pharmacological treatment for myalgic encephalomyelitis/chronic fatigue syndrome - a scoping mixed methods review.2020 · review
Summary
This scoping mixed methods review asked what non-pharmacological treatments for ME/CFS do and what patients find important. It identified 16 papers from European studies, searching January 2009 to January 2019 and updating to 18 March 2020. Effect studies examined CBT, activity pacing and multidisciplinary rehabilitation including CBT and GET; qualitative studies examined CBT, GET self-help, self-management education, multimodal specialist care and the Lightening Process. CBT findings included reduced fatigue: Janse et al. reported 43% in iCBT groups reached normal fatigue vs 15% in waiting-list controls; Nijhof et al. reported school attendance 84% vs 51%, and 75% vs 16% reached full attendance at 6 months; Tummers et al. reported 33% vs 9% with clinically reduced fatigue in one study. Activity pacing and rehabilitation effects were inconsistent; Nunez et al. found worse SF-36 pain scores after 1 year in the rehabilitation group. Pinxsterhuis et al. found no group difference in physical functioning after 6 or 12 months. Janse et al. reported no serious adverse events; Cheshire et al. reported some felt worse with GET. The authors state CBT relieved fatigue but long-term effects need more investigation, and activity-pacing and rehabilitation studies are scarce with inconsistent effects.
- Management of chronic fatigue syndrome/myalgic encephalomyelitis in a pediatric population: A scoping review.2020 · review
Summary
This scoping review examined peer-reviewed research on managing chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in a pediatric population aged under 18 years. The authors searched electronic databases and included 29 peer-reviewed research articles; no new participants were enrolled. The review grouped findings under nutrition/dietary components, exercise therapy, psychosocial factors, and multifaceted treatment. Included studies evaluated CBT with biofeedback, the Lightning Process plus standard medical care, aerobic graded exercise versus progressive resistance training, graded activity/exercise with family sessions, dietary changes, pacing versus STAIRway to Health, and other programs. Outcomes included fatigue severity, school attendance, physical function, anxiety and depression, quality of life, and global health. The review reports that included studies found lower fatigue severity and higher school attendance with CBT plus biofeedback, improvement with Lightning Process plus standard medical care, and no significant difference between aerobic graded exercise and progressive resistance training for physical capacity and QOL, while fatigue and depressive symptoms improved only in the aerobic group. No harms, side effects, worsening or withdrawals were reported in the recorded data. The authors state a lack of research in younger children and insufficient evidence for dietary modifications or supplements in prepubescent children.
- Graded exercise therapy does not restore the ability to work in ME/CFS - Rethinking of a Cochrane review.2020 · review
Summary
This review examined the amended Cochrane exercise review and the eight randomised controlled trials it included, with data from 1518 participants with ME/CFS from all diagnostic criteria. The treatments compared were exercise therapy versus no-treatment, relaxation and flexibility, or adaptive pacing. Outcomes included fatigue, physical functioning, objective exercise measures, quality of life, symptom count, and work. The review reports that exercise therapy probably reduces fatigue by 3.4 points on the Chalder fatigue scale (0 to 33) compared with no-treatment or relaxation and flexibility after 12 to 26 weeks; the effect after 52 to 70 weeks is uncertain. Physical functioning may moderately improve after 12 to 24 weeks (low evidence), and the effect after 52 to 70 weeks is uncertain; compared with adaptive pacing, exercise therapy may slightly improve physical functioning after 24 and 52 weeks. The authors report that objective outcomes in most included studies showed no objective improvement. In PACE (n = 640), 6MWT was 35.3 for no-treatment, GET had no effect on fitness, and symptom count did not differ significantly between GET and SMC (p = 0.0916) or GET and APT (p = 0.23). In an Oxford Brookes survey (n = 2,274), worsening after treatment was reported by 81.1% for GET, 85.9% for GET combined with CBT, and 58.3% for CBT combined with GET. In Wearden et al. (1998), 34.3% (23/67) complied fully with graded exercise versus 78.3% (54 of the 69 patients) with exercise placebo.
- Treating medically unexplained symptoms via improving access to psychological therapy (IAPT): major limitations identified.2020 · review
Summary
This review examined Improving Access to Psychological Therapies (IAPT) treatment protocols and early treatment data for medically unexplained symptoms, specifically ME/CFS; it enrolled no patients itself. It reports Kellett et al. IAPT service data: 172 MUS patients were treated out of 10,469 referred. Moving to recovery for depression was 32.33% for LTC and 29.35% for MUS; for anxiety it was 30.43% for LTC and 29.03% for MUS. Reliable improvement for depression was 39.07% for LTC and 33.70% for MUS; for anxiety it was 47.14% for LTC and 45.16% for MUS. Overall reliable recovery for MUS was 17.39%, and deterioration was 4.32%. Seventy-eight patients dropped out during treatment stages and 61 dropped out before treatment or did not complete treatment; 45.25% of MUS patients treated by IAPT did not complete treatment or dropped out after entering, and 4.6% completed intensive CBT. In Collin et al., 435 patients were followed for 1 year post-CBT; approximately 1/3rd reported some benefits, 5.7% counted themselves as no longer having ME/CFS, and 90%+ continued to report ME/CFS. Geraghty et al. found the majority of patients did not report CBT to be helpful, most found GET unhelpful or detrimental, and the biggest percentage reported self-pacing or guided pacing as most beneficial. Deary et al. found null to moderate size effects for reducing somatic symptoms. Edwards et al. reported most interventions out-perform usual care, even self-help guides. The authors state many patients with MUS, particularly ME/CFS, are unlikely to benefit from attending IAPT.
- Child and adolescent chronic fatigue syndrome/myalgic encephalomyelitis: where are we now?2019 · review
Summary
This review examined recent evidence on CFS/ME in children and young people, including impact, treatment and prognosis. It reported no enrolment, follow-up or treatment-duration figures for its own study and did not set out a search date or number of included studies. The review described PACE, an adult randomized controlled trial, as comparing SMC alone with SMC plus APT, CBT or GET; PACE demonstrated that CBT and GET added to SMC performed better as outpatient treatments than APT added to SMC or SMC alone. GETSET, an adult self-help graded exercise trial, reported that guided self-help added to SMC had a moderate effect on fatigue but less effect on physical functioning for those waiting for clinic therapy. In children and young people, five systematic randomized controlled trials demonstrated benefit from CBT treatment, while there was little evidence for GET. Burgess et al. reported improved physical functioning and social adjustment after a home-based, family-focused rehabilitative approach for severely affected housebound adolescents, but no substantial improvements in fatigue in all participants. Crawley et al. reported the Lightning Process plus SMC compared with SMC in mildly and moderately affected adolescents. A large online CBT trial was described as in progress. GETSET identified no serious adverse reactions in self-help GET in adults with CFS/ME. No withdrawal data were reported. The authors stated that current evidence is hampered by different diagnostic criteria, the heterogeneous nature of the condition, and limited number of small studies; they also stated that the evidence base in CYP is more limited.
- Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities.2019 · review
Summary
This review asks why pathophysiological insights in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) might point to treatments, and it examines treatment data for antioxidant and anti-inflammatory options. It reports no primary enrolment or analysis; it discusses patients diagnosed with ME/CFS by international consensus or Fukuda criteria and reviews CBT, GET, curcumin, NAC, CoQ10, melatonin, probiotics/prebiotics and molecular hydrogen. For the PACE trial, it reports that a year of CBT produced modest and short-term reductions in fatigue of some 10% compared with an untreated control group and a non-significant worsening of distance walked in six minutes. It also reports that CBT and GET reduced self-reported fatigue by some 13% compared with no treatment after 52 weeks, that GET improved six-minute walking distance by 31m compared with no treatment, and that GET for 12 months was associated with a 67m improvement versus 22m with specialist medical care alone. In 60 patients selected by international consensus criteria, graded exercise over a 12-month period was reported to worsen physical function and pain. Hydrogen-rich water studies in Parkinson’s disease (1,000 mL/day over a 48-week period) and rheumatoid arthritis (500 mL of 1 ppm for four weeks) reported improvements versus controls. The authors state these data are promising yet preliminary.
- Work Rehabilitation and Medical Retirement for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. A Review and Appraisal of Diagnostic Strategies.2019 · review
Summary
This review asked whether work rehabilitation and medical retirement strategies, including CBT and GET, restore work ability in adults with ME/CFS. It searched PubMed, Medline, the Cochrane Database of Clinical Trials and Web of Science for literature published before April 2019 and reviewed 38 CBT and/or GET studies that reported on work status. Treatments included CBT, GET, graded activity, pacing, and antidepressants. Outcomes were employment, work hours, benefits, and fatigue. In Akagi 2001 et al. (n = 94), those who worked increased from 15 to 27, but the dropout rate was 46% (43/94). In Fulcher and White (n = 66), 39% were working or studying at least part time at trial entry, compared with 47% after treatment. McDermott et al. reported 9.2% (9/98) returned to work full time and 6.1% (6/98) part-time. In the PACE trial (n = 641), lost employment remained the same (84%) after CBT and increased from 83% to 86% after GET; income benefits increased from 10% to 13% (CBT) and from 14 to 20% (GET). Wittkowski et al. had two of six patients drop out; Marlin et al. (1998) reported 69% (49/71) lost to follow up. The authors state limitations include different selection criteria and variable follow-up periods.
- ME/CFS og Aktivitetsregulering: En litteraturstudie om mennesker med ME/CFS sine erfaringer med aktivitetsregulering2019 · review
- Graded exercise therapy for myalgic encephalomyelitis/chronic fatigue syndrome is not effective and unsafe. Re-analysis of a Cochrane review.2018 · review
Summary
This paper is a re-analysis of a Cochrane review of graded exercise therapy (GET) for chronic fatigue syndrome (CFS/ME). The review included eight randomised controlled studies and reported data from 1510 participants; the re-analysis examined those trials and objective outcomes. GET was compared with control groups or other interventions. In Fulcher, exercise capacity in the GET group improved by 4.3 per cent more than in its control group by 26 weeks, and patients reported improvement on a self-rated clinical global impression score of 1 or 2. In PACE, the net improvement in EQ-5D quality of life after GET over adaptive pacing at 52 weeks was 1 per cent; there was no statistically significant difference in CFS symptom count between GET and SMC (p = 0.0916) or APT (p = 0.23) at 52 weeks. The 6-minute walk benchmark was matched by 6.3 per cent in the GET group and 5 per cent in the SMC group, implying an effect of GET of 1.3 per cent (2/160). In FINE, there were no differences between pragmatic rehabilitation and GP treatment as usual on step test measures at 20 or 70 weeks. Wallman reported a 15 per cent drop in VO2max after GET. Harms included worsening of symptoms in 40 per cent of participants in one report; 37.3 per cent dropped out of the two graded exercise groups combined versus 21.7 per cent from the two control groups combined. The authors state most studies failed to report adverse reactions.
- Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome.2017 · review
Summary
This comprehensive review examines benefits and harms of treatments for CFS/ME and makes recommendations. It reports no single enrolled or analysed total. Among the included studies, a phase II rintatolimod trial had 92 patients and a phase III trial had 234 patients; a rituximab RCT had 30 patients, with sustained overall improvement in 67% of CFS/ME patients versus 13% of controls. The PACE trial had 640 patients; a recovery paper reported 22% recovered in the CBT and GET groups, compared with 8% in the APT group and 7% in the SMC-only group. A survey of 828 Norwegian CFS subjects reported pacing useful in 96%, and 79% of patients with experience of graded training considered it worsened their health. CoQ10 plus NADH was studied in 80 patients, with maximum heart rate p=0.022. The review also describes harms: three patients administered acyclovir withdrew due to reversible renal failure, and two out of 13 participants developed neutropenia. The authors state no firm conclusions can be drawn because the few RCTs were small-scale, with a high risk of bias, and used different case definitions; nutritional studies were very limited, mostly small and without long-term follow-up.
- PACE investigators' response is misleading regarding patient survey results.2017 · review
Summary
This Open Peer Commentary Article reviews patient survey data published between 2001 and 2015 on ME/CFS. Five major patient surveys by Action for ME and The ME Association are pooled. Surveys asked patients about availability, helpfulness, improvement, worsening, or disability benefits for therapies including GET, CBT and pacing. In Action for ME 2011a (977 respondents), 48 per cent responded ‘yes’ for GET and 66 per cent for CBT being available on the NHS, compared with 90–94 per cent for pacing, medications and fatigue/condition management. In The ME Association 2010 survey (3099 respondents), 82 per cent wanted pacing, 28 per cent CBT and 24 per cent GET. In The ME Association 2010 survey (n = 4217), 22 per cent reported improvement with GET, 26 per cent with CBT and 71 per cent with pacing; 57 per cent reported worse symptoms from GET, 20 per cent from CBT and 5 per cent from pacing. The ME Association 2015 reported a net increase in patients on disability benefits after GET courses (+13%) and CBT courses (+10%), compared with a net decrease after pacing courses (−1%). The author states survey limitations should be borne in mind.
- The PACE Trial Invalidates the Use of Cognitive Behavioral and Graded Exercise Therapy in Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: A Review2016 · review
Summary
The review examines the PACE trial and its follow-up articles from doctor and patient perspectives to assess CBT and GET in ME/CFS. The PACE trial was a multicenter trial in England involving 641 patients with ME/CFS. It compared cognitive behavioral therapy (CBT), graded exercise therapy (GET), adaptive pacing therapy, and specialist medical care. At 52 weeks, the review reports no difference in long-term outcomes between these treatments and a null effect. On the 6-minute walk test, the GET group walked 379 m within 6 min, an adjusted difference of 35 m beyond specialist medical care; the CBT group walked 354 m, 4 m beyond adaptive pacing therapy but 1.5 m less than specialist medical care. The review states these improvements did not reach statistical significance, for which an increase of at least 86 m was required. It reports that 22% of participants were considered recovered in both CBT and GET groups. Receipt of income benefits increased from 10% to 13% with CBT and from 14% to 20% with GET; illness/disability benefits increased from 32% to 38% and from 31% to 36%; income protection or private pensions increased by 100% in both groups. Harms reported in PACE included an increase in ME/CFS symptoms in 46%, musculoskeletal adverse events in 31%, neurological adverse events in 19%, and non-serious adverse events in 93%; 49% reported 4 and 51% more than 4 such events. Serious adverse events were 2% in CBT and 1% in the other 3 groups. 33 (5%) of 640 participants were lost to follow-up. The PACE authors stated recovery beyond 52 weeks was uncertain.
- Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: an evidence-based approach to diagnosis and management by clinicians.2015 · review
Summary
This review was written from the viewpoint of the treating clinician to educate health care professionals and the public about Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). It reports no enrolled or analysed participant numbers. The authors describe supportive, symptomatic care and discuss pacing, graded exercise therapy (GET), medications for fatigue including stimulants and modafinil, fludrocortisone 0.1–0.2 mg/day or midodrine 10 mg up to four times daily, increased salt and electrolyte intake with fluids, isoprinosine (Imunovir), CoQ10 100–400 mg daily, eicosapentaenoic acid from omega-3 fish oil, tai chi and supportive yoga, meditation, long-term antibiotics/anti-parasitic/antiviral therapy, and psychotropic medications. They report that a study by Jason LA, Benton M (2009) found that those who stay within their energy envelope have significant improvements in physical functioning and fatigue severity compared to those who exceed their envelope. They also cite two randomized trials showing Rintatolimod (Ampligen®) benefits patients in the first three years of the illness who are more disabled. The review states GET is contraindicated and can be harmful for patients with ME/CFS using the CCC criteria, and that patients who go beyond their body’s available energy envelope will develop PEM. It states medications for fatigue are not generally recommended due to limited effectiveness and that stimulants have not been effective for cognitive dysfunction. It states fludrocortisone or midodrine help some patients, and that salt and fluids often help increase blood volume for fewer OI symptoms. The authors state there is no specific treatment for ME/CFS to date.
- Energy Conservation/Envelope Theory Interventions to Help Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.2013 · review
Summary
This review provides the theoretical and conceptual background for the Energy Envelope Theory and reviews evidence of its treatment efficacy in ME/CFS. It summarizes rehabilitation studies using energy conservation, pacing, and buddy/mentor support rather than a single trial. In one study, twelve patients with ME/CFS were recruited; half received a buddy and mentor for four months and half were controls who received no intervention; recipients had significant decreases in fatigue severity while controls had significant increases. A randomized study of forty-seven participants found significant increases in self-esteem, well-being, mastery, work, energy, and interpersonal relationships. A thirty-participant randomized buddy study reported greater reductions in fatigue severity and increases in vitality. In a trial of one hundred and fourteen patients randomly assigned to four interventions, those able to stay within energy envelopes had significant improvements in physical functioning and fatigue severity. Pacing programs were also summarized: Goudsmit et al. found differences for fatigue, somatic symptoms, and self-efficacy maintained at 12-month follow-up; Wallman et al. reported 91% rated themselves better and none felt worse; White et al. reported APT had little effect. Surveys cited found 26% of 2,338 respondents felt worse after CBT, 33.1% much worse and 23.4% slightly worse after graded exercise, and 34% worse after graded exercise. The authors note limitations to patient surveys because fidelity of interventions is not always clear.
- Chronic fatigue syndrome: traditional and community-based approaches to rehabilitation.2004 · review
Summary
This narrative review summarised and critically reviewed existing studies of psychological and psychosocial rehabilitation for chronic fatigue syndrome (CFS), searching Medline, PSYCHINFO, CINAHAL, ERIC and the Science Citation Index. Reviewed treatments included CBT with graded activity, graded exercise, activity pacing, supportive counselling, multidisciplinary inpatient and community-based programmes. Sharpe et al. 1996 reported 73% CBT achieved satisfactory outcome vs. 27% usual care, 73% vs. 23% improved function by >10 points, and 63% vs. 20% improved work status. Fulcher & White 1997 reported 51% in the exercise group improved vs. 27% of controls. Wearden et al. 1998 reported exercise improved fatigue and functional work capacity at 12 and 26 weeks; fluoxetine improved depression at 12 weeks, not sustained at 26 weeks. Powell et al. 2001 reported all three intervention groups improved more than controls at one-year follow-up. Ridsdale et al. 2001 found no differences between CBT and counselling at 3 and 6 months; 53% of the original sample were fatigue cases at 6 months. Marlin et al. 1998 reported 61% returned to gainful employment, 27% functioned at a level equivalent to employment, and 12% remained on disability. Dropout rates included 42% in exercise + fluoxetine, 38% CBT in Prins et al. 2001, and 36% cognitive therapy in Ridsdale et al. 2001. The authors state current evidence for complete and enduring benefit of any single approach remains relatively weak, and many studies are limited by absence of a placebo control group, high dropout rates and selection bias.